CUMULATIVE SUPPLEMENT 8
AUGUST 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 8

August 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 8
AUGUST 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BAXTER PHARMACEUTICAL PRODUCTS INC (BAXTER PHARM PROD)	BAXTER HEALTHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
CIBA VISION CORP DIV NOVARTIS CO (CIBA)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
CIBA VISION OPHTHALMICS (CIBA VISION OPHTHLMC)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
MARSAM PHARMACEUTICALS INC (MARSAM PHARMS)	MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)
OHMEDA PHARMACEUTICAL PRODUCTS DIV (OHMEDA)	BAXTER HEATHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ROBERTS LABORATORIES INC (ROBERTS LABS)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ROBERTS PHARMACEUTICAL CORP (ROBERTS PHARM)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	MAR 2001	JUN 2001	SEP 2001
DRUG PRODUCTS LISTED	10360	10372	10155	
SINGLE SOURCE	2682 (25.9%)	2696 (26.0%)	2665 (26.2%)	
MULTISOURCE	7568 (73.1%)	7566 (72.9%)	7380 (72.7%)	
THERAPEUTICALLY EQUIVALENT	7257 (70.0%)	7263 (70.0%)	7078 (69.7%)	
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	303 (2.9%)	302 (3.0%)	
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	2	6	3	
NUMBER OF APPLICANTS	594	582	579	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product throuth the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

1.6 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Metaxalone tablets were reviewed in the Drug Efficacy Study Implementation program. FDA published a Federal Register notice on August 15, 1974 (39 FR 29396) finding metaxalone tablets to be effective in the treatment of discomfort associated with acute, painful musculo-skeletal conditions. The Federal Register notice did not require the conduct of a bioavailability/bioequivalence study as a condition of marketing.

On March 6, 2001, URL Mutual Pharmaceutical Co. Inc submitted a citizen petition (Docket No. 01P-0117/CP1) asking FDA to reclassify the drug product metaxalone tablets from one not presenting bioequivalence problems to one that requires an in vivo demonstration of bioequivalence as a condition of approval for an ANDA. To support these assertions, the petition included results of two in vivo bioequivalence fasting studies and three separate in vitro dissolution tests. After a careful review of the data submitted by Mutual, the agency agreed that the firm has demonstrated a lack of correlation between in vitro dissolution and in vivo bioequivalence data of oral metaxalone tablets in two bioequivalence studies. The failure of both Mutual formulations to meet the 90% confidence intervals further supports the lack of in vitro/in vivo correlations.

Therefore, in accordance with our policy as enunciated in Section 1.9 of the Introduction to the 21st Edition of the Orange Book, we are providing a 60 day period in which interested parties may submit comments. The closing date for the comments will be November 30, 2001. The comments should be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. These comments should include scientific data either supporting or disagreeing with our proposal to change the therapeutic equivalence category for metaxalone tablets from a "non bioproblem" to a "bioproblem" drug.

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

	@ MIKART	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC
	@	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

TRIAPRIN

	@ DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

	@ ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB	ABLE	325MG;50MG;40MG	N40390 001	JUL 23, 2001	JUL	NEWA
AB		500MG;50MG;40MG	N40394 001	JUL 23, 2001	JUL	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE

AB		WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001	MAR	NEWA

FIORICET W/ CODEINE

AB	+	NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CFTG

PHRENILIN WITH CAFFEINE AND CODEINE

>A>	AB	AMARIN PHARMS	325MG;50MG;40MG;30MG	N74911 001	AUG 22, 2001	AUG	NEWA

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	+	MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001	MAY	NEWA
AA			300MG;30MG	N40419 002	MAY 31, 2001	MAY	NEWA
AA			300MG;60MG	N40419 003	MAY 31, 2001	MAY	NEWA

CAPITAL WITH CODEINE

		@ CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418 001	JUN 27, 2001	JUN	NEWA
AA	+	MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992	JUN	CDFR
			500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	JUN	CDFR
	+		500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	JUN	CDFR
AA		PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998	JUN	CDFR

		ACETAMINOPHEN; HYDROCODONE BITARTRATE						
		TABLET; ORAL						
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
>D>	+	WATSON LABS	325MG;7.5MG	N40248 001	APR 28, 2000	AUG	DISC	
>A>	@		325MG;7.5MG	N40248 001	APR 28, 2000	AUG	DISC	
	+		325MG;7.5MG	N40248 001	APR 28, 2000	JUL	DISC	
	+		750MG;10MG	N40094 004	MAR 22, 1999	APR	NEWA	
		LORTAB						
AA	+	WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	JAN	CAHN	
		NORCO						
AA		WATSON LABS	325MG;7.5MG	N40148 003	SEP 12, 2000	APR	NEWA	
AA	+		325MG;7.5MG	N40148 003	SEP 12, 2000	JUL	CRLD	
		ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE						
		TABLET; ORAL						
		PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN						
AB		ABLE	650MG;100MG	N75838 001	JUL 11, 2001	JUL	NEWA	
	@	HALSEY	325MG;50MG	N70115 001	JUN 12, 1985	MAY	DISC	
	@		650MG;100MG	N70116 001	JUN 12, 1985	MAY	DISC	
AB		MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001	FEB	NEWA	
AB		VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001	FEB	NEWA	
>A>		ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE						
>A>		TABLET; ORAL						
>A>		ULTRACET						
>A>	+	JOHNSON RW	325MG;37.5MG	N21123 001	AUG 15, 2001	AUG	NEWA	
		ACYCLOVIR SODIUM						
		INJECTABLE; INJECTION						
		ACYCLOVIR						
AP		GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75627 001	MAR 28, 2001	MAR	NEWA	
		ALBUTEROL						
		AEROSOL, METERED; INHALATION						
		ALBUTEROL						
AB		ARMSTRONG PHARMS	0.09MG/INH	N72273 001	AUG 14, 1996	JUN	CAHN	
		ALBUTEROL SULFATE						
		AEROSOL, METERED; INHALATION						
		VENTOLIN HFA						
	+	GLAXO	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	APR	NEWA	
		CAPSULE; INHALATION						
		VENTOLIN ROTACAPS						
	@	GLAXO WELLCOME	EQ 0.2MG BASE	N19489 001	MAY 04, 1988	JUL	DISC	
		SOLUTION; INHALATION						
		ACCUNEB						
	+	DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001	APR	NEWA	
	+		EQ 0.042% BASE	N20949 001	APR 30, 2001	APR	NEWA	
		ALBUTEROL SULFATE						
AN		NEPHRON	EQ 0.5% BASE	N75664 001	JUN 26, 2001	JUN	NEWA	
AN		ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001	FEB	NEWA	
		VENTOLIN						
	@	GLAXO WELLCOME	EQ 0.083% BASE	N19773 001	APR 23, 1992	JUL	DISC	

	@	EQ 0.5% BASE	N19269 002	JAN 16, 1987	JUL	DISC
	TABLET; ORAL					
	@ GLAXO WELLCOME	EQ 2MG BASE	N19112 001	JUL 10, 1986	JUN	DISC
	@	EQ 4MG BASE	N19112 002	JUL 10, 1986	JUN	DISC
	ALBUTEROL SULFATE; IPRATROPIUM BROMIDE					
	SOLUTION; INHALATION					
	DUONEB					
+	DEY	EQ 0.083% BASE;0.017%	N20950 001	MAR 21, 2001	MAR	NEWA
	ALLOPURINOL					
	TABLET; ORAL					
	ZYLOPRIM					
AB	PROMETHEUS LABS	100MG	N16084 001	AUG 19, 1966	MAY	CAHN
AB +		300MG	N16084 002	JAN 14, 1974	MAY	CAHN
	ALMOTRIPTAN MALATE					
	TABLET; ORAL					
	AXERT					
	PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	MAY	NEWA
+		EQ 12.5MG BASE	N21001 002	MAY 07, 2001	MAY	NEWA
	AMIKACIN SULFATE					
	INJECTABLE; INJECTION					
	AMIKACIN SULFATE					
	@ ABBOTT	EQ 250MG BASE/ML	N63265 001	NOV 30, 1994	APR	DISC
	@	EQ 250MG BASE/ML	N63266 001	OCT 31, 1994	APR	DISC
	@	EQ 250MG BASE/ML	N64099 001	JUN 20, 1995	MAY	DISC
	@ ELKINS SINN	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992	APR	DISC
	AMINOCAPROIC ACID					
	TABLET; ORAL					
	AMICAR					
AB +	IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG
	AMINOCAPROIC					
AB	MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA
	AMIODARONE HYDROCHLORIDE					
	TABLET; ORAL					
	AMIODARONE HCL					
AB	BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA
AB	TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA
	AMITRIPTYLINE HYDROCHLORIDE					
	TABLET; ORAL					
	AMITRIPTYLINE HCL					
	@ TEVA	75MG	N85030 001	NOV 22, 1976	JUL	DISC
	AMOXICILLIN					
	CAPSULE; ORAL					
	AMOXICILLIN					
	@ LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
	@	500MG	N62528 002	AUG 07, 1985	FEB	WDRP

@ MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC	
@	500MG	N62067 002	AUG 14, 1980	APR	DISC	
@ TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC	
@	500MG	N63031 001	FEB 28, 1989	APR	DISC	
TRIMOX						
@ APOTHECON	250MG	N63099 001	MAR 20, 1992	APR	DISC	
@	500MG	N63099 002	MAR 20, 1992	APR	DISC	
WYMOX						
@ WYETH AYERST	250MG	N62120 001	APR 28, 1978	APR	DISC	
@	500MG	N62120 002	APR 28, 1978	APR	DISC	
FOR SUSPENSION; ORAL						
TRIMOX						
@ APOTHECON	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC	
@	125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC	
@	250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC	
AMOXICILLIN; CLAVULANATE POTASSIUM						
FOR SUSPENSION; ORAL						
AUGMENTIN ES-600						
+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001	JUN	NEWA	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE						
TABLET; ORAL						
ADDERALL 7.5						
SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CTEC	
AMPHOTERICIN B						
INJECTABLE; INJECTION						
AMPHOTERICIN B						
@ ABBOTT	50MG/VIAL	N64141 001	DEC 23, 1996	MAY	DISC	
INJECTABLE, LIPID COMPLEX; INJECTION						
AMPHOTEC						
+ INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN	
+	100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN	
AMPICILLIN SODIUM						
INJECTABLE; INJECTION						
AMPICILLIN SODIUM						
@ ELKINS SINN	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	MAY	DISC	
@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	MAY	DISC	
@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	MAY	DISC	
@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	MAY	DISC	
@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	MAY	DISC	
@ HANFORD GC	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR	DISC	
@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC	
@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC	
@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC	
@	EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY	DISC	
@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC	

@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC
@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC
@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC
@ IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY	DISC
@	EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY	DISC
@ MARSAM	EQ 10GM BASE/VIAL	N62994 001	SEP 15, 1988	JUL	DISC
OMNIPEN-N					
@ WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY	DISC
@	EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY	DISC
@	EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY	DISC
@	EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY	DISC
@	EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY	DISC
TOTACILLIN-N					
SMITHKLINE BEECHAM	EQ 10GM BASE/VIAL	N60677 006	MAY 04, 1976	JUL	CTEC

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE					
@ BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY	DISC
@	EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY	DISC

FOR SUSPENSION; ORAL

@ MYLAN	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC
@	EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC
TOTACILLIN					
@ SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
@	EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL

PROBAMPACIN					
@ TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA					
@ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO					
@ PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	JUL	CAHN
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	JUL	CAHN
@ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC					
+ SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/				

		VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+	ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	SEP 21, 2000	FEB	NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

LANORINAL

@	LANNETT	325MG;50MG;40MG	N86986 002	OCT 18, 1985	JUL	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

AB	GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996	JAN	CAHN

INVAGESIC FORTE

AB	GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996	JAN	CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND 65

@	EON	389MG;32.4MG;65MG	N80044 002	SEP 16, 1983	MAY	DISC

PROPOXYPHENE COMPOUND-65

@	GENEVA PHARMS	389MG;32.4MG;65MG	N83101 002	JUN 24, 1985	MAY	DISC

ATENOLOL

TABLET; ORAL

ATENOLOL

@	GENPHARM	25MG	N74126 003	AUG 26, 1998	JUL	DISC
@		50MG	N74126 001	MAR 23, 1994	JUL	DISC
@		100MG	N74126 002	MAR 23, 1994	JUL	DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

LIPITOR

	PFIZER	EQ 10MG BASE	N20702 001	DEC 17, 1996	MAR	CAHN
		EQ 20MG BASE	N20702 002	DEC 17, 1996	MAR	CAHN
		EQ 40MG BASE	N20702 003	DEC 17, 1996	MAR	CAHN
+		EQ 80MG BASE	N20702 004	APR 07, 2000	MAR	CAHN

ATROPINE SULFATE

INJECTABLE; IM-IV-SC

ATROPINE SULFATE ANSYR PLASTIC

	ABBOTT	0.05MG/ML	N21146 002	JUL 09, 2001	JUL	NEWA

	+	0.1MG/ML	N21146 001	JUL 09, 2001	JUL	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

	@ INWOOD LABS	0.025MG;2.5MG	N85509 001	MAR 09, 1978	FEB	WDRP
>D>	@ LANNETT	0.025MG;2.5MG	N85372 001	FEB 21, 1978	AUG	CMFD
>A> AA		0.025MG;2.5MG	N85372 001	FEB 21, 1978	AUG	CMFD
	@ R AND S PHARMA	0.025MG;2.5MG	N85035 001	JUL 05, 1977	MAY	DISC
	@ WEST WARD	0.025MG;2.5MG	N87765 001	MAR 15, 1982	JUL	DISC

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

>D>	@ EON	0.025MG;2.5MG	N86173 001	AUG 28, 1981	AUG	CMFD
>A> AA		0.025MG;2.5MG	N86173 001	AUG 28, 1981	AUG	CMFD
	@ PVT FORM	0.025MG;2.5MG	N85766 001	DEC 22, 1978	MAY	DISC

AURANOFIN
CAPSULE; ORAL
RIDAURA

	+ PROMETHEUS LABS	3MG	N18689 001	MAY 24, 1985	MAY	CAHN

AZATHIOPRINE
TABLET; ORAL
IMURAN

	@ PROMETHEUS LABS	25MG	N16324 002	MAR 21, 1980	MAY	CAHN
AB	+	50MG	N16324 001	MAR 20, 1968	MAY	CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE
FOR SUSPENSION; TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

	@ PFIZER	EQ 1GM BASE;EQ 100MG BASE	N50762 001	DEC 18, 1998	MAY	DISC

BACITRACIN ZINC
POWDER; FOR RX COMPOUNDING
ZIBA-RX

	@ PHARMA TEK	500,000 UNITS/BOT	N61737 001	APR 26, 1973	MAY	DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
NEO-POLYCIN

	@ DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP

BENDROFLUMETHIAZIDE; NADOLOL
TABLET; ORAL
CORZIDE

>D>	APOTHECON	5MG;40MG	N18647 001	MAY 25, 1983	AUG	CAHN
>D>	+	5MG;80MG	N18647 002	MAY 25, 1983	AUG	CAHN
>A>	KING PHARMS	5MG;40MG	N18647 001	MAY 25, 1983	AUG	CAHN
>A>	+	5MG;80MG	N18647 002	MAY 25, 1983	AUG	CAHN

BENZQUINAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
EMETE-CON
+ PFIZER — EQ 50MG BASE/VIAL — N16820 001 — MAR 20, 1974 — MAY — CAHN

BETAMETHASONE DIPROPIONATE
CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE
@ CLAY PARK — EQ 0.05% BASE — N74579 001 — NOV 26, 1997 — APR — DISC
>D> DISC; TOPICAL
>D> DIPROSONE
>D> + SCHERING — EQ 0.1% BASE — N17829 001 — MAY 24, 1977 — AUG — DISC
>A> @ — EQ 0.1% BASE — N17829 001 — MAY 24, 1977 — AUG — DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE
CREAM; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
AB ALTANA — EQ 0.05% BASE;1% — N75502 001 — JUN 05, 2001 — JUN — NEWA
AB TARO — EQ 0.05% BASE;1% — N75673 001 — MAY 29, 2001 — MAY — NEWA
LOTRISONE
AB + SCHERING — EQ 0.05% BASE;1% — N18827 001 — JUL 10, 1984 — MAY — CFTG

BETAXOLOL HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
BETAXOLOL HCL
AT BAUSCH AND LOMB — EQ 0.5% BASE — N75630 001 — APR 12, 2001 — APR — NEWA

BETHANECHOL CHLORIDE
INJECTABLE; INJECTION
URECHOLINE
>D> @ MERCK — 5MG/ML — N06536 001 — OCT 12, 1948 — AUG — CAHN
>A> @ SIDMAK LABS — 5MG/ML — N06536 001 — OCT 12, 1948 — AUG — CAHN
TABLET; ORAL
DUVOID
@ WELLSPRING PHARM — 10MG — N86262 001 — MAR 22, 1978 — JUN — CAHN
@ — 25MG — N86263 001 — MAR 22, 1978 — JUN — CAHN
@ — 50MG — N85882 003 — MAR 22, 1978 — JUN — CAHN
URECHOLINE
>D> @ MERCK — 5MG — N06536 003 — FEB 03, 1949 — AUG — CAHN
>D> @ — 10MG — N06536 002 — OCT 12, 1948 — AUG — CAHN
>D> @ — 25MG — N06536 004 — OCT 12, 1948 — AUG — CAHN
>D> @ — 50MG — N06536 005 — JUN 24, 1980 — AUG — CAHN
>A> @ SIDMAK LABS — 5MG — N06536 003 — FEB 03, 1949 — AUG — CAHN
>A> @ — 10MG — N06536 002 — OCT 12, 1948 — AUG — CAHN
>A> @ — 25MG — N06536 004 — OCT 12, 1948 — AUG — CAHN
>A> @ — 50MG — N06536 005 — JUN 24, 1980 — AUG — CAHN

BIMATOPROST
SOLUTION/DROPS; OPHTHALMIC
LUMIGAN
+ ALLERGAN — 0.03% — N21275 001 — MAR 16, 2001 — MAR — NEWA

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

+	PROMETHEUS LABS	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC
+		262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	JUN	DISC

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	COPLEY PHARM	5MG	N75644 001	JUN 26, 2001	JUN	NEWA
AB		10MG	N75644 002	JUN 26, 2001	JUN	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ APOTHECON	2.5MG;6.25MG	N75642 002	DEC 27, 2000	JUN	DISC
	@	5MG;6.25MG	N75642 001	DEC 27, 2000	JUN	DISC
	@	10MG;6.25MG	N75642 003	DEC 27, 2000	JUN	DISC
AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA
AB		5MG;6.25MG	N75686 002	JAN 19, 2001	JAN	NEWA
AB		10MG;6.25MG	N75686 003	JAN 19, 2001	JAN	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

	@ ALLERGAN	0.5%	N20490 001	MAR 13, 1997	APR	DISC

ALPHAGAN P

+	ALLERGAN	0.15%	N21262 001	MAR 16, 2001	MAR	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; SPINAL

MARCAINE

AP	+	ABBOTT	0.75%	N18692 001	MAY 04, 1984	JUN	CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

AP	+	RECKITT BENCKISER	EQ 0.3MG BASE/ML	N18401 001	DEC 29, 1981	JUL	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN SR

	GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996	APR	CTEC
		100MG	N20358 002	OCT 04, 1996	APR	CTEC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

AB	BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986	MAR	CFTG
AB		10MG	N18731 002	SEP 29, 1986	MAR	CFTG
AB		15MG	N18731 003	APR 22, 1996	MAR	NEWA
AB	+	30MG	N18731 004	APR 22, 1996	JUN	CFTG

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL
BUSPIRONE HCL

AB	DANBURY PHARMA	5MG	N74253 001	MAR 28, 2001	MAR	NEWA
AB		10MG	N74253 002	MAR 28, 2001	MAR	NEWA
AB	MYLAN	15MG	N75272 003	MAR 28, 2001	MAR	NEWA
AB	MYLAN TECHNOLOGIES	30MG	N76008 001	JUN 28, 2001	JUN	NEWA
AB	PAR PHARM	7.5MG	N75467 002	MAR 28, 2001	MAR	NEWA

BUTABARBITAL SODIUM
TABLET; ORAL
BUTISOL SODIUM

+	WALLACE LABS	15MG	N00793 002	JUN 05, 1939	MAY	CTEC
	SODIUM BUTABARBITAL					
	@ LANNETT	15MG	N85849 001	AUG 21, 1978	MAY	DISC
	@	30MG	N85866 001	JUL 20, 1978	MAY	DISC

BUTORPHANOL TARTRATE
SPRAY, METERED; NASAL

>A>		BUTORPHANOL TARTRATE					
>A>	AB	MYLAN	1MG/SPRAY	N75759 001	AUG 08, 2001	AUG	NEWA
>A>		STADOL					
>D>	+	BRISTOL MYERS SQUIBB	1MG/SPRAY	N19890 001	DEC 12, 1991	AUG	CFTG
>A>	AB +		1MG/SPRAY	N19890 001	DEC 12, 1991	AUG	CFTG

CALCITONIN, SALMON
INJECTABLE; INJECTION
CALCITONIN-SALMON

	@ ASTRAZENECA	200 IU/ML	N73690 001	APR 14, 1995	JUN	DISC

CALCIUM ACETATE
CAPSULE; ORAL
PHOSLO

>D>		BRAINTREE	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	AUG	DISC
>A>		@	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	AUG	DISC
			EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	APR	NEWA
>D>	+		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	AUG	DISC
>A>	+ @		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	AUG	DISC
	+		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	APR	NEWA
>A>		PHOSLO GELCAPS					
>A>	+	BRAINTREE	EQ 169MG CALCIUM	N21160 003	APR 02, 2001	AUG	NEWA

CAPTOPRIL
TABLET; ORAL
CAPTOPRIL

AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996	JAN	CAHN
AB		25MG	N74481 002	FEB 13, 1996	JAN	CAHN
AB		50MG	N74481 003	FEB 13, 1996	JAN	CAHN
AB		100MG	N74481 004	FEB 13, 1996	JAN	CAHN

CARBACHOL
SOLUTION; INTRAOCULAR
CARBASTAT

AT	NOVARTIS	0.01%	N73677 001	APR 28, 1995	FEB	CAHN

CARBAMAZEPINE
TABLET, CHEWABLE; ORAL
CARBAMAZEPINE

AB	CARACO	100MG	N75712 001	JUL 05, 2001	JUL	NEWA

TABLET, EXTENDED RELEASE; ORAL
TEGRETOL-XR

	NOVARTIS	100MG	N20234 001	MAR 25, 1996	JUL	CRLD
		200MG	N20234 002	MAR 25, 1996	JUL	CRLD

CARBIDOPA; LEVODOPA
TABLET; ORAL
CARBIDOPA AND LEVODOPA

	@ SCS	10MG;100MG	N74080 001	MAR 25, 1994	FEB	WDRP
	@	25MG;100MG	N74080 002	MAR 25, 1994	FEB	WDRP
	@	25MG;250MG	N74080 003	MAR 25, 1994	FEB	WDRP

CARISOPRODOL
TABLET; ORAL
CARISOPRODOL

AA	ABLE	350MG	N40421 001	JUN 21, 2001	JUN	NEWA

CASPOFUNGIN ACETATE
INJECTABLE; IV (INFUSION)
CANCIDAS

+	MERCK RES	50MG/VIAL	N21227 001	JAN 26, 2001	JAN	NEWA
+		70MG/VIAL	N21227 002	JAN 26, 2001	JAN	NEWA

CEFACLOR
CAPSULE; ORAL
CECLOR

AB	CEPH INTL	EQ 250MG BASE	N62205 001	JUL 28, 1979	JUN	CAHN
AB		EQ 500MG BASE	N62205 002	JUL 28, 1979	JUN	CAHN

FOR SUSPENSION; ORAL
CEFACLOR

	@ ZENITH GOLDLINE	EQ 125MG BASE/5ML	N64087 001	APR 28, 1995	MAY	DISC
	@	EQ 187MG BASE/5ML	N64086 001	APR 28, 1995	MAY	DISC
	@	EQ 250MG BASE/5ML	N64085 001	APR 28, 1995	MAY	DISC

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD

	LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	APR	CTEC
AB	+	EQ 500MG BASE	N50673 002	JUN 28, 1996	JAN	CFTG

CEFACLOR

AB	ZENITH GOLDLINE	EQ 500MG BASE	N65057 001	JAN 05, 2001	JAN	NEWA

	CEFADROXIL/CEFADROXIL HEMIHYDRATE						
	TABLET; ORAL						
	CEFADROXIL						
	@ ZENITH GOLDLINE	EQ 1GM BASE	N62774	001	APR 08, 1987	MAY	DISC
	CEFAMANDOLE NAFATE						
	INJECTABLE; INJECTION						
	MANDOL						
	@ LILLY	EQ 1GM BASE/VIAL	N62560	001	SEP 10, 1985	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62560	002	SEP 10, 1985	MAY	DISC
	CEFAZOLIN SODIUM						
	INJECTABLE; INJECTION						
	CEFAZOLIN SODIUM						
	@ TEVA	EQ 250MG BASE/VIAL	N63016	001	MAR 14, 1989	APR	DISC
	@	EQ 500MG BASE/VIAL	N63016	002	MAR 14, 1989	APR	DISC
	@	EQ 1GM BASE/VIAL	N63016	003	MAR 14, 1989	APR	DISC
	KEFZOL						
	@ LILLY	EQ 500MG BASE/VIAL	N62557	001	SEP 10, 1985	MAY	DISC
	@	EQ 1GM BASE/VIAL	N62557	002	SEP 10, 1985	MAY	DISC
>A>	CEFDITOREN PIVOXIL						
>A>	TABLET; ORAL						
>A>	SPECTRACEF						
>A>	+ TAP PHARM	200MG	N21222	001	AUG 29, 2001	AUG	NEWA
	CEFONICID SODIUM						
>D>	INJECTABLE; INJECTION						
>D>	MONOCID						
>D>	+ SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N50579	001	MAY 23, 1984	AUG	DISC
>A>	+ @	EQ 500MG BASE/VIAL	N50579	001	MAY 23, 1984	AUG	DISC
>D>	+	EQ 1GM BASE/VIAL	N50579	002	MAY 23, 1984	AUG	DISC
>A>	+ @	EQ 1GM BASE/VIAL	N50579	002	MAY 23, 1984	AUG	DISC
	@	EQ 1GM BASE/VIAL	N63295	001	JUL 26, 1993	APR	DISC
>D>	+	EQ 10GM BASE/VIAL	N50579	004	MAY 23, 1984	AUG	DISC
>A>	@	EQ 10GM BASE/VIAL	N50579	004	MAY 23, 1984	AUG	DISC
	CEFOPERAZONE SODIUM						
	INJECTABLE; INJECTION						
	CEFOBID						
	@ PFIZER	EQ 1GM BASE/VIAL	N63333	001	MAR 31, 1995	MAY	DISC
	@	EQ 2GM BASE/VIAL	N63333	002	MAR 31, 1995	MAY	DISC
	CEFORANIDE						
	INJECTABLE; INJECTION						
	PRECEF						
	@ APOTHECON	500MG/VIAL	N62579	001	NOV 26, 1984	MAY	DISC
	@	1GM/VIAL	N62579	002	NOV 26, 1984	MAY	DISC
	@	2GM/VIAL	N62579	003	NOV 26, 1984	MAY	DISC
	@	10GM/VIAL	N62579	004	NOV 26, 1984	MAY	DISC
	@	20GM/VIAL	N62579	005	NOV 26, 1984	MAY	DISC

CEFOXITIN SODIUM
INJECTABLE; INJECTION
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ MERCK	EQ 20MG BASE/ML	N50581 003	SEP 20, 1984	JUL	DISC	
@	EQ 40MG BASE/ML	N50581 004	SEP 20, 1984	JUL	DISC	

CEFTAZIDIME
INJECTABLE; INJECTION
TAZICEF

AP ABBOTT	500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN	
AP	1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN	
AP	1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN	
AP	2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN	
AP	2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN	
AP	6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN	

TAZIDIME IN PLASTIC CONTAINER

@ LILLY	1GM/VIAL	N62739 001	JUL 10, 1986	MAY	DISC	
@	2GM/VIAL	N62739 002	JUL 10, 1986	MAY	DISC	

CEFUROXIME SODIUM
INJECTABLE; IM-IV
CEFUROXIME

AB AM PHARM PARTNERS	EQ 750MG BASE/VIAL	N65001 001	MAY 30, 2001	MAY	NEWA	
AB TEVA	EQ 750MG BASE/VIAL	N64192 002	APR 16, 1998	MAY	CDFR	

CEFUROXIME SODIUM

AB HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997	MAY	CDFR	

KEFUROX

AB LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986	MAY	CDFR	

ZINACEF

AB + GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983	MAY	CDFR	

INJECTABLE; INJECTION
CEFUROXIME

AP AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001 002	MAY 30, 2001	MAY	NEWA	

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

+ B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA	
+	EQ 30MG BASE/ML	N50780 002	FEB 21, 2001	FEB	NEWA	

KEFUROX IN PLASTIC CONTAINER

@ LILLY	EQ 1.5GM BASE/VIAL	N62590 002	JAN 10, 1986	MAY	DISC	

INJECTABLE; INTRAVENOUS

@ LILLY	EQ 750MG BASE/VIAL	N62590 001	JAN 10, 1986	MAY	DISC	

CEPHALEXIN
CAPSULE; ORAL
CEPHALEXIN

@ STEVENS J	EQ 500MG BASE	N62869 001	MAR 17, 1988	JUL	DISC	
@ TEVA	EQ 500MG BASE	N62823 001	FEB 05, 1988	MAY	DISC	

KEFLEX

AB CEPH INTL	EQ 250MG BASE	N62118 001	MAR 27, 1978	JUN	CAHN	
AB	EQ 500MG BASE	N62118 002	MAR 27, 1978	JUN	CAHN	

FOR SUSPENSION; ORAL
CEPHALEXIN

@ BARR	EQ 125MG BASE/5ML	N62778 001	AUG 06, 1987	MAY	DISC	

AB	RANBAXY	EQ 125MG BASE/5ML	N65081 001	JUL 27, 2001	JUL	NEWA
AB		EQ 250MG BASE/5ML	N65081 002	JUL 27, 2001	JUL	NEWA
	KEFLEX					
	+ CEPH INTL	EQ 100MG BASE/ML	N62117 001	MAR 27, 1978	JUN	CAHN
AB		EQ 125MG BASE/5ML	N62117 002	MAR 27, 1978	JUN	CAHN
AB	+	EQ 250MG BASE/5ML	N62117 003	MAR 27, 1978	JUN	CAHN
	TABLET; ORAL					
	KEFLET					
	@ LILLY	EQ 250MG BASE	N62745 001	DEC 01, 1986	JUL	DISC
	@	EQ 500MG BASE	N62745 002	DEC 01, 1986	JUL	DISC
	CEPHALOTHIN SODIUM					
	INJECTABLE; INJECTION					
	KEFLIN IN PLASTIC CONTAINER					
	@ LILLY	EQ 1GM BASE/VIAL	N62549 001	SEP 10, 1985	APR	DISC
	@	EQ 2GM BASE/VIAL	N62549 002	SEP 10, 1985	APR	DISC
>A>	CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE					
>A>	TABLET, EXTENDED RELEASE; ORAL					
>A>	ZYRTEC-D 12 HOUR					
>A>	+ PFIZER	5MG;120MG	N21150 001	AUG 10, 2001	AUG	NEWA
	CHLORAMPHENICOL					
	CAPSULE; ORAL					
	CHLORAMPHENICOL					
	@ ZENITH GOLDLINE	250MG	N62247 001	APR 28, 1980	MAY	DISC
	CHLOROMYCETIN					
	@ PARKEDALE	50MG	N60591 001	DEC 08, 1950	MAY	DISC
	@	100MG	N60591 003	DEC 08, 1950	MAY	DISC
	@	250MG	N60591 002	DEC 08, 1950	MAY	DISC
	MYCHEL					
	+ ARMENPHARM	250MG	N60851 001	JUN 20, 1967	MAY	CRLD
	SOLUTION/DROPS; OPHTHALMIC					
	CHLORAMPHENICOL					
	@ AKORN	0.5%	N62042 001	AUG 31, 1981	FEB	WDRP
	@ ALCON	0.5%	N62628 001	SEP 25, 1985	MAY	DISC
	CHLOROPTIC					
	+ ALLERGAN	0.5%	N50091 001	MAR 20, 1968	MAY	CTEC
	CHLORDIAZEPOXIDE HYDROCHLORIDE					
	CAPSULE; ORAL					
	CHLORDIAZACHEL					
	@ RACHELLE	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
	@	10MG	N84639 001	MAY 11, 1976	FEB	WDRP
	@	25MG	N85087 001	MAY 11, 1976	FEB	WDRP
	CHLORDIAZEPOXIDE HCL					
	@ FERRANTE	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
	@	10MG	N85119 001	SEP 02, 1976	FEB	WDRP
	@	25MG	N85120 001	SEP 02, 1976	FEB	WDRP
	@ GENEVA PHARMS	5MG	N84678 001	JUN 15, 1976	JUL	DISC
	@	10MG	N84041 001	JUN 15, 1976	MAY	DISC
	@	25MG	N84679 002	SEP 07, 1976	MAY	DISC
	@ IMPAX LABS	5MG	N86213 001	JUL 10, 1979	JUL	DISC

	@	25MG	N86212 001	JUL 10, 1979	JUL	DISC
	@ ROSEMONT	5MG	N84644 001	FEB 24, 1976	MAY	DISC
	@	25MG	N84645 001	FEB 24, 1976	JUL	DISC
	CHLOROQUINE PHOSPHATE					
	TABLET; ORAL					
	CHLOROQUINE PHOSPHATE					
	@ TEVA	EQ 150MG BASE	N87504 001	JAN 13, 1982	JUL	DISC
	CHLOROTHIAZIDE					
	TABLET; ORAL					
	CHLOROTHIAZIDE					
	@ ABC HOLDING	250MG	N85569 001	MAR 08, 1978	MAY	DISC
	@ CHELSEA LABS	250MG	N86795 001	AUG 15, 1983	JUL	DISC
	@ DANBURY PHARMA	250MG	N85173 001	NOV 04, 1977	MAY	DISC
	CHLORPHENIRAMINE MALEATE					
	INJECTABLE; INJECTION					
	CHLORPHENIRAMINE MALEATE					
	@ STERIS	10MG/ML	N86096 001	OCT 09, 1979	JUL	DISC
	TABLET; ORAL					
	@ GENEVA PHARMS	4MG	N80961 001	DEC 20, 1972	MAY	DISC
AA	+ ICN	4MG	N80598 001	FEB 11, 1972	MAY	CRLD
	@ PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
	@ WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP
	CHLORPROMAZINE HYDROCHLORIDE					
	INJECTABLE; INJECTION					
	CHLORPROMAZINE HCL					
	@ STERIS	25MG/ML	N80365 001	FEB 13, 1974	MAY	DISC
	CHLORTHALIDONE					
	TABLET; ORAL					
	CHLORTHALIDONE					
	@ GENEVA PHARMS	25MG	N87380 001	MAY 01, 1981	JUL	DISC
	CHLORZOXAZONE					
	TABLET; ORAL					
	CHLORZOXAZONE					
	@ DANBURY PHARMA	500MG	N81019 001	JUL 29, 1991	MAY	DISC
	CIMETIDINE					
	TABLET; ORAL					
	CIMETIDINE					
AB	GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN
AB		300MG	N74506 002	JAN 24, 1996	JAN	CAHN
AB		400MG	N74506 003	JAN 24, 1996	JAN	CAHN
AB		800MG	N74506 004	JAN 24, 1996	JAN	CAHN
	CINOXACIN					
	CAPSULE; ORAL					
	CINOBAC					
	LILLY	250MG	N18067 001	JUN 13, 1980	JUL	CTEC

	+		500MG	N18067 002	JUN 13, 1980	JUL	CTEC
		CINOXACIN					
		@ TEVA	250MG	N73005 001	FEB 28, 1992	JUL	DISC
		@	500MG	N73006 001	FEB 28, 1992	JUL	DISC
		CLINDAMYCIN HYDROCHLORIDE					
		CAPSULE; ORAL					
		CLEOCIN HCL					
AB	+	PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG
		CLINDAMYCIN HCL					
AB		RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
AB			EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA
		CLINDAMYCIN PHOSPHATE					
		INJECTABLE; INJECTION					
		CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+	PHARMACIA AND UPJOHN	EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG
		CLINDAMYCIN PHOSPHATE					
		@ ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC
		@ ELKINS SINN	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC
		@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC
		@ GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
		@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC
		@ LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC
		CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		ABBOTT	EQ 6MG BASE/ML	N65027 001	JUN 29, 2001	JUN	NEWA
AP			EQ 12MG BASE/ML	N65027 002	JUN 29, 2001	JUN	NEWA
AP			EQ 18MG BASE/ML	N65027 003	JUN 29, 2001	JUN	NEWA
		SOLUTION; TOPICAL					
		CLINDAMYCIN PHOSPHATE					
		@ COPLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC
		@ TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC
		CLOBETASOL PROPIONATE					
		CREAM; TOPICAL					
		CLOBETASOL PROPIONATE					
AB1		STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA
>A> AB2			0.05%	N75733 001	AUG 22, 2001	AUG	NEWA
		CLOMIPRAMINE HYDROCHLORIDE					
		CAPSULE; ORAL					
		ANAFRANIL					
AB		TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989	JUN	CAHN
AB	+		50MG	N19906 002	DEC 29, 1989	JUN	CAHN
AB			75MG	N19906 003	DEC 29, 1989	JUN	CAHN
		CLONAZEPAM					
		TABLET; ORAL					
		CLONAZEPAM					
AB		CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
AB			1MG	N75423 002	APR 27, 2001	APR	NEWA
AB			2MG	N75423 003	APR 27, 2001	APR	NEWA

CLORAZEPATE DIPOTASSIUM
CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

		@ ABLE	3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
		@	7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
		@	15MG	N71779 001	JUL 14, 1987	JAN	DISC

TABLET; ORAL

		@ GENEVA PHARMS	3.75MG	N72512 001	MAY 11, 1990	JUL	DISC

CORTICOTROPIN
INJECTABLE; INJECTION
H.P. ACTHAR GEL

>D>	BC +	AVENTIS	40 UNITS/ML	N08372 006	FEB 06, 1956	AUG	CAHN
>D>	BC +		80 UNITS/ML	N08372 008	FEB 06, 1956	AUG	CAHN
>A>	BC +	QUESTCOR PHARMS	40 UNITS/ML	N08372 006	FEB 06, 1956	AUG	CAHN
>A>	BC +		80 UNITS/ML	N08372 008	FEB 06, 1956	AUG	CAHN

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE

		@ CHELSEA LABS	25MG	N85884 001	MAY 15, 1978	MAY	DISC

CROMOLYN SODIUM
SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

	AT	NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA

CYCLACILLIN
TABLET; ORAL
CYCLACILLIN

		@ TEVA	250MG	N62895 001	AUG 04, 1988	MAY	DISC
		@	500MG	N62895 002	AUG 04, 1988	MAY	DISC

CYPROHEPTADINE HYDROCHLORIDE
TABLET; ORAL
CYPROHEPTADINE HCL

		@ GENEVA PHARMS	4MG	N86808 001	FEB 24, 1981	JUL	DISC

DACARBAZINE
INJECTABLE; INJECTION
DACARBAZINE

	AP	BEDFORD	200MG/VIAL	N75812 001	JUN 15, 2001	JUN	NEWA

DELAVIRDINE MESYLATE
TABLET; ORAL
RESCRIPTOR

>D>		+ AGOURON	100MG	N20705 001	APR 04, 1997	AUG	CRLD
>A>			100MG	N20705 001	APR 04, 1997	AUG	CRLD
>A>		+	200MG	N20705 002	JUL 14, 1999	AUG	NEWA

DESERPIDINE; HYDROCHLOROTHIAZIDE							
TABLET; ORAL							
ORETICYL 25							
@ ABBOTT	0.125MG;25MG	N12148 001	DEC 14, 1959	MAR	DISC		
ORETICYL 50							
@ ABBOTT	0.125MG;50MG	N12148 003	DEC 14, 1959	MAR	DISC		
ORETICYL FORTE							
@ ABBOTT	0.25MG;25MG	N12148 002	DEC 14, 1959	MAR	DISC		
DESONIDE							
OINTMENT; TOPICAL							
DESONIDE							
AB ALTANA	0.05%	N75751 001	MAR 12, 2001	MAR	NEWA		
DEXAMETHASONE							
TABLET; ORAL							
DEXAMETHASONE							
@ DANBURY PHARMA	0.75MG	N80968 001	MAY 03, 1973	MAY	DISC		
DEXAMETHASONE SODIUM PHOSPHATE							
INJECTABLE; INJECTION							
DEXAMETHASONE SODIUM PHOSPHATE							
@ DELL LABS	EQ 4MG PHOSPHATE/ML	N83161 001	JUN 06, 1978	FEB	WDRP		
@ GENSIA SICOR PHARMS	EQ 4MG PHOSPHATE/ML	N81125 001	AUG 31, 1990	MAY	DISC		
OINTMENT; OPHTHALMIC							
DECADRON							
@ MERCK	EQ 0.05% PHOSPHATE	N11977 001	SEP 02, 1959	MAY	DISC		
MAXIDEX							
+ ALCON	EQ 0.05% PHOSPHATE	N83342 001	OCT 23, 1973	MAY	CTEC		
SOLUTION/DROPS; OTIC							
DEXAMETHASONE SODIUM PHOSPHATE							
@ AKORN	EQ 0.1% PHOSPHATE	N84855 001	JUN 29, 1976	FEB	WDRP		
DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE							
SOLUTION/DROPS; OPHTHALMIC							
NEODECADRON							
+ MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001	JUL 06, 1959	MAY	CTEC		
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE							
@ ALCON UNIVERSAL	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714 001	JUL 21, 1986	MAY	DISC		
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE							
OINTMENT; OPHTHALMIC							
DEXACIDIN							
AT NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	FEB	CAHN		
@	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	MAY	DISC		
SUSPENSION/DROPS; OPHTHALMIC							
AT NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544 001	OCT 29, 1984	FEB	CAHN		

DEXTROAMPHETAMINE SULFATE
TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

AA		BARR	5MG	N40361 001	JAN 31, 2001	JAN	NEWA
AA			10MG	N40361 002	JAN 31, 2001	JAN	NEWA
		DEXTROSTAT					
AA	+	SHIRE RICHWOOD	10MG	N84051 002	MAY 29, 1975	JAN	CFTG

DIAZEPAM
GEL; RECTAL
DIASTAT

	+	XCEL PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997	JUL	CAHN
			5MG/ML	N20648 002	JUL 29, 1997	JUL	CAHN
			10MG/2ML	N20648 003	JUL 29, 1997	JUL	CAHN
			15MG/3ML	N20648 004	JUL 29, 1997	JUL	CAHN
	+		20MG/4ML	N20648 005	JUL 29, 1997	JUL	CAHN

DICLOFENAC POTASSIUM
TABLET; ORAL
DICLOFENAC POTASSIUM

AB		EON	50MG	N75582 001	FEB 23, 2001	FEB	NEWA

DICLOFENAC SODIUM
GEL; TOPICAL
SOLARAZE

	+	BIOGLAN PHARMA PLC	3%	N21005 001	OCT 16, 2000	MAR	CAHN

DICLOXACILLIN SODIUM
CAPSULE; ORAL
DYCILL

	@	SMITHKLINE BEECHAM	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC
	@		EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC

DICYCLOMINE HYDROCHLORIDE
CAPSULE; ORAL
DICYCLOMINE HCL

	@	HALSEY	10MG	N84505 001	OCT 21, 1986	MAY	DISC

INJECTABLE; INJECTION

	@	STERIS	10MG/ML	N80614 001	FEB 11, 1986	JUL	DISC

DIETHYLPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
TENUATE DOSPAN

	+	AVENTIS PHARMS	75MG	N12546 001	NOV 07, 1960	JUL	CTEC

TEPANIL TEN-TAB

	@	3M	75MG	N17956 001	MAY 25, 1977	JUL	DISC

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB2		MYLAN	120MG	N75124 002	MAR 18, 1998	MAR	CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

@	CHELSEA LABS	50MG	N85083 001	JUN 29, 1976	MAY	DISC
@	NEWTRON PHARMS	25MG	N86543 001	FEB 08, 1979	FEB	WDRP
@		50MG	N86544 001	FEB 08, 1979	FEB	WDRP

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL PRESERVATIVE FREE

@	AM PHARM PARTNERS	50MG/ML	N80586 002	JAN 10, 1973	JUL	DISC

DISULFIRAM

TABLET; ORAL

ANTABUSE

	ODYSSEY PHARMS	250MG				
+		500MG	N88482 001	DEC 08, 1983	JAN	CAHN
@	SIDMAK LABS	250MG	N88483 001	DEC 08, 1983	JAN	CAHN
@		500MG	N07883 003	NOV 03, 1970	MAR	CAHN
			N07883 002	JUN 01, 1953	MAR	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	SIDMAK LABS	EQ 1MG BASE	N75750 001	JUN 08, 2001	JUN	NEWA
AB		EQ 2MG BASE	N75750 002	JUN 08, 2001	JUN	NEWA
AB		EQ 4MG BASE	N75750 003	JUN 08, 2001	JUN	NEWA
AB		EQ 8MG BASE	N75750 004	JUN 08, 2001	JUN	NEWA
AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA
AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCHEL

@	RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP

VIBRAMYCIN

+	PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

@	TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC
@		EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC

DOXYCYCLINE HYCLATE

@	CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC
@		EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC
AB	HALSEY	EQ 50MG BASE	N61717 001	JUL 17, 1973	JUN	CAHN
@		EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC
AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN	CAHN
@		EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC

CAPSULE, COATED PELLETS; ORAL

@	SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC

INJECTABLE; INJECTION

DOXYCYCLINE HYCLATE
INJECTABLE; INJECTION
DOXYCHEL HYCLATE
@ RACHELLE — EQ 100MG BASE/VIAL — N61953 001 SEP 10, 1980 FEB WDRP
DOXYCYCLINE
@ BEDFORD — EQ 100MG BASE/VIAL — N62569 001 MAR 09, 1988 MAY DISC
@ — EQ 200MG BASE/VIAL — N62569 002 MAR 09, 1988 MAY DISC
@ ELKINS SINN — EQ 100MG BASE/VIAL — N62450 001 OCT 27, 1983 APR DISC
@ — EQ 200MG BASE/VIAL — N62450 002 OCT 27, 1983 APR DISC
DOXYCYCLINE HYCLATE
@ LEDERLE — EQ 100MG BASE/VIAL — N62992 001 FEB 16, 1989 MAY DISC
@ — EQ 200MG BASE/VIAL — N62992 002 FEB 16, 1989 MAY DISC
TABLET; ORAL
DOXY-LEMMON
@ TEVA — EQ 100MG BASE — N62581 001 MAR 15, 1985 MAY DISC
DOXYCYCLINE HYCLATE
AB HALSEY — EQ 100MG BASE — N62269 001 SEP 03, 1980 JUN CAHN
AB — EQ 100MG BASE — N62269 002 NOV 08, 1982 JUN CAHN
@ — EQ 100MG BASE — N62391 001 SEP 30, 1982 APR DISC
DOXYCYCLINE HYLATE
@ HALSEY — EQ 50MG BASE — N62269 003 SEP 03, 1980 JUN CAHN
PERIOSTAT
+ COLLAGENEX PHARMS — 20MG — N50783 001 FEB 02, 2001 FEB NEWA

DROPERIDOL; FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL
@ ASTRAZENECA — 2.5MG/ML;EQ 0.05MG BASE/ML — N72027 001 APR 13, 1989 JUL DISC

DROSPIRENONE; ETHINYL ESTRADIOL
TABLET; ORAL-28
YASMIN
+ BERLEX LABS — 3MG;0.03MG — N21098 001 MAY 11, 2001 MAY NEWA

DYCLONINE HYDROCHLORIDE
>D> SOLUTION; TOPICAL
>D> DYCLONE
>D> + ASTRAZENECA — 0.5% — N09925 002 JUN 13, 1974 AUG DISC
>A> @ — 0.5% — N09925 002 JUN 13, 1974 AUG DISC
>D> + — 1% — N09925 001 AUG 03, 1955 AUG DISC
>A> @ — 1% — N09925 001 AUG 03, 1955 AUG DISC

ENALAPRIL MALEATE
TABLET; ORAL
ENALAPRIL MALEATE
AB TARO — 2.5MG — N75657 001 JAN 23, 2001 JAN NEWA
AB — 5MG — N75657 002 JAN 23, 2001 JAN NEWA
AB — 10MG — N75657 003 JAN 23, 2001 JAN NEWA
AB — 20MG — N75657 004 JAN 23, 2001 JAN NEWA
AB TORPHARM — 2.5MG — N75178 002 MAR 23, 2001 MAR NEWA
AB — 5MG — N75178 001 MAR 23, 2001 MAR NEWA
AB — 10MG — N75178 003 MAR 23, 2001 MAR NEWA
AB — 20MG — N75178 004 MAR 23, 2001 MAR NEWA

ENFLURANE
LIQUID; INHALATION
ENFLURANE
AN MINRAD 99.9% N74396 001 JUL 29, 1994 FEB CAHN

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX
\+ AVENTIS 30MG/0.3ML N20164 001 MAR 29, 1993 APR CAHN
\+ 40MG/0.4ML N20164 002 JAN 30, 1998 APR CAHN
\+ 60MG/0.6ML N20164 003 MAR 27, 1998 APR CAHN
\+ 80MG/0.8ML N20164 004 MAR 27, 1998 APR CAHN
\+ 90MG/0.6ML N20164 006 JUN 02, 2000 APR CAHN
\+ 100MG/ML N20164 005 MAR 27, 1998 APR CAHN
\+ 120MG/0.8ML N20164 007 JUN 02, 2000 APR CAHN
\+ 150MG/ML N20164 008 JUN 02, 2000 APR CAHN

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST
\+ DENTSPLY PHARM 0.005MG/ML;1% N17751 006 AUG 30, 1976 APR CAHN
\+ 0.005MG/ML;1.5% N17751 007 AUG 30, 1976 APR CAHN

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
@ DENTSPLY PHARM 0.005MG/ML;0.5% N17751 004 AUG 30, 1976 APR CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCAINE HCL W/ EPINEPHRINE
@ INTL MEDICATION 0.01MG/ML;1% N86402 001 FEB 04, 1980 JUL DISC
@ STERIS 0.01MG/ML;1% N80377 003 FEB 20, 1974 JUL DISC
@ 0.01MG/ML;2% N80377 004 FEB 20, 1974 JUL DISC
LIDOCATON
@ PHARMATON 0.02MG/ML;2% N84728 001 AUG 17, 1983 FEB WDRP

ERGOCALCIFEROL
CAPSULE; ORAL
VITAMIN D
@ IMPAX LABS 50,000 IU N80951 001 JUL 13, 1973 FEB DISC

ERGOLOID MESYLATES
TABLET; ORAL
ERGOLOID MESYLATES
@ DANBURY PHARMA 1MG N87244 001 AUG 16, 1982 JUL DISC
TABLET; SUBLINGUAL
@ DANBURY PHARMA 1MG N87183 001 APR 16, 1981 JUL DISC

ERYTHROMYCIN
SOLUTION; TOPICAL
ERYTHROMYCIN
@ CLAY PARK 2% N63038 001 JAN 11, 1991 APR DISC

AT	2%	N63038 001	JAN 11, 1991	MAY	CMFD
TABLET, DELAYED RELEASE; ORAL					
E-BASE					
@ BARR	333MG	N63028 001	MAY 15, 1990	APR	DISC
ILOTYCIN					
@ DISTA	250MG	N61910 001	FEB 27, 1975	MAY	DISC
ERYTHROMYCIN ESTOLATE					
CAPSULE; ORAL					
ERYTHROMYCIN ESTOLATE					
+ BARR	EQ 250MG BASE	N62162 002	JUN 15, 1981	MAY	CTEC
@ DANBURY PHARMA	EQ 250MG BASE	N62087 001	JUN 14, 1979	APR	DISC
ILOSONE					
@ LILLY	EQ 125MG BASE	N61897 001	JAN 06, 1975	MAY	DISC
@	EQ 250MG BASE	N61897 002	JAN 06, 1975	MAY	DISC
FOR SUSPENSION; ORAL					
@ DISTA	EQ 125MG BASE/5ML	N61893 001	JAN 06, 1975	MAY	DISC
SUSPENSION/DROPS; ORAL					
@ LILLY	EQ 100MG BASE/ML	N61894 003	JAN 07, 1975	APR	DISC
TABLET; ORAL					
@ LILLY	EQ 500MG BASE	N61896 001	JAN 03, 1975	APR	DISC
TABLET, CHEWABLE; ORAL					
@ DISTA	EQ 125MG BASE	N61895 001	JAN 03, 1975	MAY	DISC
@	EQ 250MG BASE	N61895 002	JAN 03, 1975	MAY	DISC
ERYTHROMYCIN ETHYLSUCCINATE					
TABLET; ORAL					
ERYTHROMYCIN ETHYLSUCCINATE					
@ BARR	EQ 400MG BASE	N62256 001	APR 28, 1980	MAY	DISC
ERYTHROMYCIN GLUCEPTATE					
INJECTABLE; INJECTION					
ILOTYCIN GLUCEPTATE					
@ DISTA	EQ 250MG BASE/VIAL	N50370 001	JUN 23, 1964	JUL	DISC
@	EQ 500MG BASE/VIAL	N50370 002	JUN 23, 1964	JUL	DISC
@	EQ 1GM BASE/VIAL	N50370 003	JUN 23, 1964	JUL	DISC
ERYTHROMYCIN STEARATE					
TABLET; ORAL					
ERYTHROMYCIN STEARATE					
@ BARR	EQ 500MG BASE	N63179 001	MAY 15, 1990	MAY	DISC
@ ZENITH GOLDLINE	EQ 250MG BASE	N61461 001	SEP 04, 1971	MAY	DISC
@	EQ 500MG BASE	N61461 002	APR 11, 1980	MAY	DISC
WYAMYCIN S					
@ WYETH AYERST	EQ 250MG BASE	N61675 001	OCT 06, 1972	APR	DISC
@	EQ 500MG BASE	N61675 002	JUL 13, 1973	APR	DISC
ESOMEPRAZOLE MAGNESIUM					
CAPSULE, DELAYED REL PELLETS; ORAL					
NEXIUM					
+ ASTRAZENECA	EQ 20MG BASE	N21153 001	FEB 20, 2001	FEB	NEWA
+	EQ 40MG BASE	N21153 002	FEB 20, 2001	FEB	NEWA

ESTRADIOL VALERATE
INJECTABLE; INJECTION
DELESTROGEN

>D>		+	BRISTOL MYERS SQUIBB	10MG/ML	N09402 002	AUG 18, 1962	AUG	CAHN
>D>	AO	+		20MG/ML	N09402 004	JUN 23, 1961	AUG	CAHN
>D>	AO	+		40MG/ML	N09402 003	FEB 24, 1961	AUG	CAHN
>A>		+	KING PHARMS	10MG/ML	N09402 002	AUG 18, 1962	AUG	CAHN
>A>	AO	+		20MG/ML	N09402 004	JUN 23, 1961	AUG	CAHN
>A>	AO	+		40MG/ML	N09402 003	FEB 24, 1961	AUG	CAHN

ESTRADIOL; NORETHINDRONE ACETATE
FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

		NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	AUG 07, 1998	MAR	CAHN
	+		0.05MG/24HR;0.25MG/24HR	N20870 002	AUG 07, 1998	MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET; ORAL-28
PREMPRO

+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20527 001	NOV 17, 1995	JAN	CTNA
+		0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	JAN	CTNA

PREMPRO (PREMARIN;CYCRIN)

+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	JAN	CTNA

ESTROGENS, ESTERIFIED
TABLET; ORAL
ESTRATAB

@	SOLVAY	0.3MG	N86715 001	APR 08, 1981	JUL	DISC
@		0.625MG	N83209 001	JUN 17, 1977	JUL	DISC

MENEST

+	MONARCH PHARMS	0.3MG	N84951 001	SEP 28, 1977	JUL	CTEC
		0.625MG	N84948 001	SEP 28, 1977	JUL	CTEC

ESTROPIPATE
TABLET; ORAL
ORTHO-EST

AB	WOMEN FIRST HLTHCARE	0.75MG	N89567 001	FEB 27, 1991	JAN	CAHN
AB		1.5MG	N89582 001	JUL 17, 1991	JAN	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL
TABLET; ORAL-21
ALESSE

AB	+ WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997	APR	CTEC

AVIANE-21

AB	DURAMED	0.02MG;0.1MG	N75796 002	APR 30, 2001	APR	NEWA

TABLET; ORAL-21
ENPRESSE-21

AB	DURAMED	0.03MG,0.04MG;0.03MG,0.05MG;0.075MG,0.125MG	N75809 001	JUL 16, 2001	JUL	NEWA

ETHINYL ESTRADIOL; LEVONORGESTREL
TABLET; ORAL-28
ALESSE

AB	WYETH AYERST	0.02MG;0.1MG	N20683	002	MAR 27, 1997	APR	CTEC

AVIANE-28

AB	DURAMED	0.02MG;0.1MG	N75796	001	APR 30, 2001	APR	NEWA

ENPRESSE-28

AB	DURAMED	0.03MG,0.04MG;0.03MG,0.05MG; 0.075MG,0.125MG	N75809	002	JUL 16, 2001	JUL	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
TABLET; ORAL-28
LOESTRIN FE 1.5/30

AB +	PARKE DAVIS	0.03MG;1.5MG	N17355	001	APR 30, 1973	FEB	CFTG

LOESTRIN FE 1/20

AB +	PARKE DAVIS	0.02MG;1MG	N17354	001	APR 30, 1973	FEB	CFTG

MICROGESTIN FE 1.5/30

AB	WATSON LABS	0.03MG;1.5MG	N75548	001	FEB 05, 2001	FEB	NEWA

MICROGESTIN FE 1/20

AB	WATSON LABS	0.02MG;1MG	N75647	001	FEB 05, 2001	FEB	NEWA

ETHOSUXIMIDE
SYRUP; ORAL
ZARONTIN

AA +	PARKE DAVIS	250MG/5ML	N80258	001	FEB 13, 1974	JAN	CRLD

ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

@	DENTSPLY PHARM	0.5%	N17751	003	AUG 30, 1976	APR	CAHN
+		1%	N17751	005	AUG 30, 1976	APR	CAHN

ETODOLAC
TABLET, EXTENDED RELEASE; ORAL
ETODOLAC

AB	TEVA	400MG	N75665	003	FEB 05, 2001	FEB	NEWA

ETOPOSIDE PHOSPHATE
INJECTABLE; INJECTION
ETOPOPHOS PRESERVATIVE FREE

@	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N20906	001	FEB 27, 1998	JUN	DISC
@		EQ 1GM BASE/VIAL	N20906	002	FEB 27, 1998	JUN	NEWA

FAMCICLOVIR
TABLET; ORAL
FAMVIR

	NOVARTIS	125MG	N20363	003	DEC 11, 1995	JAN	CAHN
		250MG	N20363	001	APR 26, 1996	JAN	CAHN
+		500MG	N20363	002	JUN 29, 1994	JAN	CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP		AM PHARM PARTNERS	10MG/ML	N75709 001	APR 16, 2001	APR	NEWA
AP		APOTHECON	10MG/ML	N75707 001	APR 16, 2001	APR	NEWA
		@	10MG/ML	N75707 001	APR 16, 2001	MAY	DISC
AP		BEDFORD	10MG/ML	N75651 001	APR 16, 2001	APR	NEWA
AP			10MG/ML	N75684 001	APR 16, 2001	APR	NEWA
AP		ESI LEDERLE	10MG/ML	N75488 001	APR 16, 2001	APR	NEWA
AP		FAULDING	10MG/ML	N75705 001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE

AP		AM PHARM PARTNERS	10MG/ML	N75813 001	APR 16, 2001	APR	NEWA
AP		APOTHECON	10MG/ML	N75708 001	APR 16, 2001	APR	NEWA
		@	10MG/ML	N75708 001	APR 16, 2001	MAY	DISC
AP		BEDFORD	10MG/ML	N75622 001	APR 16, 2001	APR	NEWA
AP		BEN VENUE	10MG/ML	N75825 001	APR 17, 2001	APR	NEWA
AP		ESI LEDERLE	10MG/ML	N75486 001	APR 16, 2001	APR	NEWA
AP		FAULDING	10MG/ML	N75669 001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	0.4MG/ML	N75591 001	MAY 10, 2001	MAY	NEWA

PEPCID

AP	+	MERCK	10MG/ML	N19510 001	NOV 04, 1986	APR	CFTG

PEPCID PRESERVATIVE FREE

AP	+	MERCK	10MG/ML	N19510 004	NOV 04, 1986	APR	CFTG

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	+	MERCK	0.4MG/ML	N20249 001	FEB 18, 1994	MAY	CFTG

TABLET; ORAL

FAMOTIDINE

AB		CARLSBAD	20MG	N75805 001	APR 16, 2001	APR	NEWA
AB			40MG	N75805 002	APR 16, 2001	APR	NEWA
AB		DANBURY PHARMA	20MG	N75062 002	APR 16, 2001	APR	NEWA
AB			40MG	N75062 001	APR 16, 2001	APR	NEWA
AB		DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001	APR	NEWA
AB			40MG	N75718 002	APR 16, 2001	APR	NEWA
AB		EON	20MG	N75793 001	APR 16, 2001	APR	NEWA
AB			40MG	N75793 002	APR 16, 2001	APR	NEWA
AB		GENEVA PHARMS	20MG	N75302 001	APR 16, 2001	APR	NEWA
AB			40MG	N75302 002	APR 16, 2001	APR	NEWA
AB		GENPHARM	20MG	N75457 001	APR 18, 2001	APR	NEWA
AB			40MG	N75457 002	APR 18, 2001	APR	NEWA
AB		INVAMED	20MG	N75607 001	MAY 10, 2001	MAY	NEWA
AB			40MG	N75607 002	MAY 10, 2001	MAY	NEWA
AB		MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA
AB			40MG	N75704 002	APR 16, 2001	APR	NEWA
AB		TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA
AB			40MG	N75311 002	APR 16, 2001	APR	NEWA
AB		TORPHARM	20MG	N75611 001	JUL 23, 2001	JUL	NEWA
AB			40MG	N75611 002	JUL 23, 2001	JUL	NEWA
AB		WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA
AB			40MG	N75786 002	APR 16, 2001	APR	NEWA
AB		ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA
AB			40MG	N75511 002	APR 16, 2001	APR	NEWA

FAMOTIDINE
TABLET; ORAL
PEPCID

AB		MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG
AB	+		40MG	N19462 002	OCT 15, 1986	APR	CFTG

FENTANYL
FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC

		ALZA	1.2MG/24HR	N19813 003	AUG 07, 1990	MAY	CTEC
			1.8MG/24HR	N19813 002	AUG 07, 1990	MAY	CTEC
			2.4MG/24HR	N19813 001	AUG 07, 1990	MAY	CTEC

FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE PRESERVATIVE FREE

		@ MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998	JAN	DISC

FLECAINIDE ACETATE
TABLET; ORAL
FLECAINIDE ACETATE

AB		ALPHAPHARM	50MG	N75442 001	JUL 31, 2001	JUL	NEWA
AB			100MG	N75442 002	JUL 31, 2001	JUL	NEWA
AB			150MG	N75442 003	JUL 31, 2001	JUL	NEWA
		TAMBOCOR					
AB		3M	50MG	N18830 004	AUG 23, 1988	JUL	CFTG
AB			100MG	N18830 001	OCT 31, 1985	JUL	CFTG
AB	+		150MG	N18830 003	JUN 03, 1988	JUL	CFTG

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE

AP		AM PHARM PARTNERS	500MG/VIAL	N75837 001	FEB 22, 2001	FEB	NEWA

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

		@ CLAY PARK	0.01%	N86810 001	MAR 04, 1982	APR	DISC
		@	0.025%	N86811 001	MAR 04, 1982	APR	DISC

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-SYNALAR

		@ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	JUN 11, 1963	MAY	DISC

FLUOROMETHOLONE
SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP

AB		NOVARTIS	0.1%	N70185 001	FEB 27, 1986	FEB	CAHN

FLUOROURACIL
CREAM; TOPICAL
CARAC
+ DERMIK LABS 0.5% N20985 001 OCT 27, 2000 MAY CTNA

FLUOXETINE HYDROCHLORIDE
CAPSULE; ORAL
FLUOXETINE
>A> AB BARR EQ 20MG BASE N74803 001 AUG 02, 2001 AUG NEWA
>A> AB DR REDDYS LABS LTD EQ 40MG BASE N75465 003 AUG 02, 2001 AUG NEWA
>A> AB GENEVA PHARMS EQ 10MG BASE N75049 001 AUG 02, 2001 AUG NEWA
PROZAC
>D> LILLY EQ 10MG BASE N18936 006 DEC 23, 1992 AUG CFTG
>A> AB EQ 10MG BASE N18936 006 DEC 23, 1992 AUG CFTG
>D> EQ 20MG BASE N18936 001 DEC 29, 1987 AUG CFTG
>A> AB EQ 20MG BASE N18936 001 DEC 29, 1987 AUG CFTG
>D> + EQ 40MG BASE N18936 003 JUN 15, 1999 AUG CFTG
>A> AB + EQ 40MG BASE N18936 003 JUN 15, 1999 AUG CFTG
CAPSULE, DELAYED REL PELLETS; ORAL
PROZAC WEEKLY
+ LILLY EQ 90MG BASE N21235 001 FEB 26, 2001 FEB NEWA
SOLUTION; ORAL
FLUOXETINE
>A> AT TEVA EQ 20MG BASE/5ML N75506 001 AUG 02, 2001 AUG NEWA
PROZAC
>D> + LILLY EQ 20MG BASE/5ML N20101 001 APR 24, 1991 AUG CFTG
>A> AT + EQ 20MG BASE/5ML N20101 001 APR 24, 1991 AUG CFTG
TABLET; ORAL
FLUOXETINE HCL
>A> AB ALPHAPHARM EQ 10MG BASE N75755 001 AUG 02, 2001 AUG NEWA
>A> + EQ 20MG BASE N75755 002 AUG 02, 2001 AUG NEWA
PROZAC
>D> + LILLY EQ 10MG BASE N20974 001 MAR 09, 1999 AUG CFTG
>A> AB + EQ 10MG BASE N20974 001 MAR 09, 1999 AUG CFTG

FLUPHENAZINE DECANOATE
INJECTABLE; IM-SC
FLUPHENAZINE DECANOATE
>A> AO APOTEX 25MG/ML N75918 001 AUG 17, 2001 AUG NEWA

FLURAZEPAM HYDROCHLORIDE
CAPSULE; ORAL
FLURAZEPAM HCL
@ CHELSEA LABS 15MG N72368 001 MAR 30, 1989 JUL DISC
@ PUREPAC PHARM 15MG N71927 001 SEP 09, 1987 JUL DISC
@ 30MG N71551 001 SEP 09, 1987 JUL DISC

FLURBIPROFEN
TABLET; ORAL
FLURBIPROFEN
AB CARACO 50MG N75058 001 APR 27, 2001 APR NEWA
AB 100MG N75058 002 APR 27, 2001 APR NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

AB	BARR	25MG	N75897 001	JAN 25, 2001	JAN	NEWA
AB		50MG	N75897 002	JAN 25, 2001	JAN	NEWA
AB		100MG	N75897 003	JAN 25, 2001	JAN	NEWA
AB	INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA
AB		50MG	N75887 002	JAN 05, 2001	JAN	NEWA
AB		100MG	N75887 003	JAN 05, 2001	JAN	NEWA
AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA
AB		50MG	N75899 002	JAN 17, 2001	JAN	NEWA
AB		100MG	N75899 003	JAN 17, 2001	JAN	NEWA
AB	TORPHARM	25MG	N75902 001	MAY 07, 2001	MAY	NEWA
AB		50MG	N75902 002	MAY 07, 2001	MAY	NEWA
AB		100MG	N75902 003	MAY 07, 2001	MAY	NEWA
AB	WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA
AB		50MG	N75894 002	APR 18, 2001	APR	NEWA
AB		100MG	N75894 003	APR 18, 2001	APR	NEWA
AB	ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA
AB		50MG	N75898 002	MAR 12, 2001	MAR	NEWA
AB		100MG	N75898 003	MAR 12, 2001	MAR	NEWA

FOLLITROPIN ALFA
INJECTABLE; INJECTION
GONAL-F

>A>	+ SERONO	1,200 IU/VIAL	N20378 004	FEB 28, 2001	AUG	NEWA

FORMOTEROL FUMARATE
CAPSULE; INHALATION
FORADIL

	+ NOVARTIS	0.012MG/INH	N20831 001	FEB 16, 2001	FEB	NEWA

GABAPENTIN
CAPSULE; ORAL
NEURONTIN

	PFIZER	100MG	N20235 001	DEC 30, 1993	MAR	CAHN
		300MG	N20235 002	DEC 30, 1993	MAR	CAHN
	+	400MG	N20235 003	DEC 30, 1993	MAR	CAHN

GALANTAMINE HYDROBROMIDE
SOLUTION; ORAL
REMINYL

	+ JANSSEN	4MG/ML	N21224 001	JUN 22, 2001	JUN	NEWA

TABLET; ORAL

	JANSSEN	EQ 4MG BASE	N21169 001	FEB 28, 2001	FEB	NEWA
		EQ 8MG BASE	N21169 002	FEB 28, 2001	FEB	NEWA
	+	EQ 12MG BASE	N21169 003	FEB 28, 2001	FEB	NEWA

GEMFIBROZIL
TABLET; ORAL
GEMFIBROZIL

AB	GENEVA PHARMS TECH	600MG	N74615 001	SEP 29, 1995	JAN	CAHN

GENTAMICIN SULFATE
CREAM; TOPICAL
GENTAMICIN SULFATE
@ BAUSCH AND LOMB — EQ 0.1% BASE — N64056 001 APR 29, 1994 MAY DISC
INJECTABLE; INJECTION
@ GENSIA SICOR PHARMS — EQ 10MG BASE/ML — N63149 001 NOV 21, 1991 MAY DISC
@ — EQ 40MG BASE/ML — N63106 002 NOV 21, 1991 APR DISC
@ STERIS — EQ 10MG BASE/ML — N62318 002 AUG 20, 1981 APR DISC
@ — EQ 40MG BASE/ML — N62318 001 JUN 02, 1981 APR DISC
U-GENCIN
@ PHARMACIA AND UPJOHN — EQ 10MG BASE/ML — N62248 001 MAY 02, 1980 FEB WDRP
@ — EQ 40MG BASE/ML — N62248 002 MAY 02, 1980 FEB WDRP
INJECTABLE; INTRATHECAL
GARAMYCIN
@ SCHERING — EQ 2MG BASE/ML — N50505 001 OCT 01, 1979 APR DISC
OINTMENT; OPHTHALMIC
GENTACIDIN
AT NOVARTIS — EQ 0.3% BASE — N62501 001 JUL 26, 1984 FEB CAHN
@ — EQ 0.3% BASE — N62501 001 JUL 26, 1984 MAY DISC
OINTMENT; TOPICAL
GENTAMICIN SULFATE
@ BAUSCH AND LOMB — EQ 0.1% BASE — N64054 001 APR 29, 1994 MAY DISC
SOLUTION/DROPS; OPHTHALMIC
GENTACIDIN
AT NOVARTIS — EQ 0.3% BASE — N62480 001 MAR 30, 1984 FEB CAHN
GENTAMICIN SULFATE
@ ALCON UNIVERSAL — EQ 0.3% BASE — N62523 001 NOV 25, 1985 APR DISC

GLIPIZIDE
TABLET; ORAL
GLIPIZIDE
AB GENEVA PHARMS TECH — 5MG — N74542 001 JUN 20, 1995 JAN CAHN
AB — 10MG — N74542 002 JUN 20, 1995 JAN CAHN
AB TORPHARM — 5MG — N75795 001 JUN 13, 2001 JUN NEWA
AB — 10MG — N75795 002 JUN 13, 2001 JUN NEWA

GLYCOPYRROLATE
INJECTABLE; INJECTION
GLYCOPYRROLATE
@ GENSIA SICOR PHARMS — 0.2MG/ML — N81169 001 SEP 10, 1991 MAY DISC
TABLET; ORAL
ROBINUL
>A> + FIRST HORIZON — 1MG — N12827 001 AUG 11, 1961 AUG CAHN
>D> + HORIZON PHARM — 1MG — N12827 001 AUG 11, 1961 AUG CAHN
ROBINUL FORTE
>A> + FIRST HORIZON — 2MG — N12827 002 AUG 11, 1961 AUG CAHN
>D> + HORIZON PHARM — 2MG — N12827 002 AUG 11, 1961 AUG CAHN

GRANISETRON HYDROCHLORIDE
SOLUTION; ORAL
KYTRIL
+ ROCHE — EQ 2MG BASE/10ML — N21238 001 JUN 27, 2001 JUN NEWA

GRISEOFULVIN, MICROCRYSTALLINE
SUSPENSION; ORAL
GRIFULVIN V

+		J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD
	@	JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE
TABLET; ORAL
GRISACTIN ULTRA

	@	WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC
	@		250MG	N62178 002	MAR 13, 1980	APR	DISC

ULTRAGRIS-165

	@	SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992	MAY	DISC

ULTRAGRIS-330

	@	SIDMAK LABS NJ	330MG	N62646 001	JUN 30, 1992	MAY	DISC

HALOPERIDOL
TABLET; ORAL
HALOPERIDOL

	@	DANBURY PHARMA	1MG	N70982 001	MAR 06, 1987	JUL	DISC
>D>	AB	ROXANE	0.5MG	N71128 001	FEB 17, 1987	AUG	DISC
>A>	@		0.5MG	N71128 001	FEB 17, 1987	AUG	DISC
>D>	AB		1MG	N71129 001	FEB 17, 1987	AUG	DISC
>A>	@		1MG	N71129 001	FEB 17, 1987	AUG	DISC
>D>	AB		2MG	N71130 001	FEB 17, 1987	AUG	DISC
>A>	@		2MG	N71130 001	FEB 17, 1987	AUG	DISC
>D>	AB		5MG	N71131 001	FEB 17, 1987	AUG	DISC
>A>	@		5MG	N71131 001	FEB 17, 1987	AUG	DISC
>D>	AB		20MG	N71133 001	MAY 12, 1987	AUG	DISC
>A>	@		20MG	N71133 001	MAY 12, 1987	AUG	DISC

HALOPERIDOL LACTATE
CONCENTRATE; ORAL
>D> HALOPERIDOL INTENSOL

>D>	AA	ROXANE	EQ 2MG BASE/ML	N72045 001	APR 12, 1988	AUG	DISC
>A>	@		EQ 2MG BASE/ML	N72045 001	APR 12, 1988	AUG	DISC

INJECTABLE; INJECTION
HALOPERIDOL

	AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	JUN	CTNA
	AP	BEDFORD	EQ 5MG BASE/ML	N75858 001	JUN 18, 2001	JUN	NEWA
>A>	AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N76035 001	AUG 29, 2001	AUG	NEWA

HALOPERIDOL LACTATE

	AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	MAR	NEWA

HALOTHANE
LIQUID; INHALATION
HALOTHANE

	@	BH	99.99%	N84977 001	JUL 14, 1976	JAN	DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM
@ ABBOTT 10,000 UNITS/ML N40095 001 JUL 26, 1996 MAY DISC
HEPARIN SODIUM PRESERVATIVE FREE
@ PHARMA SERVE NY 1,000 UNITS/ML N86129 001 FEB 22, 1980 FEB WDRP

HOMATROPINE METHYLBROMIDE
TABLET; ORAL
HOMAPIN-10
@ MISSION PHARMA 10MG N86308 001 APR 11, 1979 JUL DISC
HOMAPIN-5
@ MISSION PHARMA 5MG N86309 001 APR 11, 1979 JUL DISC

HYALURONIDASE
INJECTABLE; INJECTION
WYDASE
@ WYETH AYERST 150 UNITS/ML N06343 002 MAR 22, 1950 JUL DISC
@ 150 UNITS/VIAL N06343 006 MAR 06, 1951 JUL DISC
@ 1,500 UNITS/VIAL N06343 005 MAR 06, 1951 JUL DISC

HYDRALAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDRALAZINE HCL
AP AM PHARM PARTNERS 20MG/ML N40388 001 MAR 13, 2001 MAR NEWA

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA 25MG;15MG;0.1MG N85549 001 SEP 29, 1977 MAY DISC

HYDROCHLOROTHIAZIDE
TABLET; ORAL
HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA 50MG N83232 001 JAN 24, 1975 MAY DISC
@ HALSEY 25MG N83972 001 OCT 03, 1974 MAY DISC
@ 50MG N83972 002 OCT 03, 1974 MAY DISC
@ IMPAX LABS 25MG N84029 001 JUL 05, 1977 MAY DISC
@ 50MG N83607 002 JUN 06, 1977 MAY DISC
@ PHARMERAL 25MG N84325 001 JUN 24, 1976 MAY DISC
@ 50MG N84324 001 JUN 24, 1976 MAY DISC
@ PVT FORM 50MG N86597 001 OCT 11, 1978 JUL DISC
@ WEST WARD 50MG N84878 001 JAN 31, 1977 MAY DISC

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
HYDRO-RESERP
@ ABC HOLDING 50MG;0.125MG N84714 002 JUN 29, 1982 MAY DISC
HYDROCHLOROTHIAZIDE W/ RESERPINE
@ DANBURY PHARMA 25MG;0.125MG N84466 001 JAN 07, 1977 MAY DISC
@ 50MG;0.125MG N84467 001 JAN 07, 1977 MAY DISC

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE AND HYDROCHLOROTHIAZIDE-50

@ WEST WARD — 50MG;0.125MG — N88189 001 MAY 10, 1984 FEB WDRP

HYDROCORTISONE

CREAM; TOPICAL

HC (HYDROCORTISONE)

@ C AND M PHARMA — 0.5% — N80482 003 MAR 20, 1973 FEB WDRP

@ — 1% — N80482 004 MAR 20, 1973 FEB WDRP

HYDROCORTISONE

@ TOPIDERM — 1% — N89273 001 FEB 17, 1989 FEB WDRP

NUTRACORT

@ HEALTHPOINT — 1% — N80442 003 APR 04, 1972 JUL DISC

PROCTOCORT

@ MONARCH PHARMS — 1% — N83011 001 APR 26, 1973 FEB DISC

LOTION; TOPICAL

ACTICORT

@ BAKER NORTON — 1% — N86535 001 FEB 04, 1981 JUL DISC

BETA-HC

@ BETA DERMAC — 1% — N89495 001 JAN 25, 1988 FEB WDRP

GLYCORT

@ HERAN — 1% — N87489 001 OCT 03, 1983 FEB WDRP

HYDROCORTISONE

@ MERICON — 0.5% — N85282 001 JUN 05, 1978 MAY DISC

@ — 1% — N85282 002 FEB 26, 1987 MAY DISC

OINTMENT; TOPICAL

HC (HYDROCORTISONE)

@ C AND M PHARMA — 1% — N80481 002 MAR 20, 1973 FEB WDRP

POWDER; FOR RX COMPOUNDING

H-CORT

@ TORCH — 100% — N87834 001 MAR 29, 1982 FEB WDRP

SOLUTION; TOPICAL

TEXACORT

AT + SIRIUS LABS — 1% — N80425 001 DEC 22, 1971 JUN CAHN

+ — 2.5% — N81271 001 APR 17, 1992 MAY CAHN

TABLET; ORAL

HYDROCORTISONE

@ LANNETT — 20MG — N85070 001 MAY 07, 1976 MAY DISC

HYDROCORTISONE ACETATE

CREAM; TOPICAL

MICORT-HC

FERNDALE LABS — 2.5% — N40396 001 FEB 27, 2001 FEB NEWA

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL

NEO-CORTEF

@ PHARMACIA AND UPJOHN — 1%;EQ 3.5MG BASE/GM — N60751 002 MAY 18, 1965 APR DISC

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

@ AKORN — 1.5%;EQ 3.5MG BASE/ML — N60188 001 OCT 26, 1968 FEB WDRP

HYDROCORTISONE VALERATE
OINTMENT; TOPICAL
HYDROCORTISONE VALERATE

AB	ALTANA	0.2%	N75085 001	JUL 31, 2001	JUL	NEWA

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION/DROPS; OTIC
NEO-OTOSOL-HC

@	ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001	AUG 25, 1983	APR	DISC

SUSPENSION/DROPS; OPHTHALMIC
CORTISPORIN

+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N50169 001	DEC 18, 1964	MAY	CTEC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	MAY	DISC

SUSPENSION/DROPS; OTIC

@	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001	NOV 06, 1985	APR	DISC

HYDROXYZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDROXYZINE HCL

@	ABBOTT	50MG/ML	N86821 001	SEP 05, 1979	JUL	DISC
@	AM PHARM PARTNERS	25MG/ML	N88184 001	MAR 31, 1983	JUL	DISC
@		50MG/ML	N88185 001	MAR 31, 1983	JUL	DISC
@	STERIS	25MG/ML	N85778 001	OCT 05, 1979	MAY	DISC

TABLET; ORAL

@	PAR PHARM	10MG	N87602 001	JAN 22, 1982	JUL	DISC
@		25MG	N87603 001	JAN 22, 1982	JUL	DISC
@		50MG	N87604 001	JAN 22, 1982	JUL	DISC

HYDROXYZINE PAMOATE
CAPSULE; ORAL
HYDROXYZINE PAMOATE

@	GENEVA PHARMS	EQ 50MG HCL	N81128 001	JUN 28, 1991	MAY	DISC
@		EQ 100MG HCL	N81129 001	JUN 28, 1991	MAY	DISC
@	VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP

IMATINIB MESYLATE
CAPSULE; ORAL
GLEEVEC

	NOVARTIS	50MG	N21335 001	MAY 10, 2001	MAY	NEWA
+		100MG	N21335 002	MAY 10, 2001	MAY	NEWA

IMIPRAMINE HYDROCHLORIDE
TABLET; ORAL
TOFRANIL

AB	TYCO HLTHCARE	10MG	N87844 001	MAY 22, 1984	JUN	CAHN
AB		25MG	N87845 001	MAY 22, 1984	JUN	CAHN
AB	+	50MG	N87846 001	MAY 22, 1984	JUN	CAHN

IMIPRAMINE PAMOATE
CAPSULE; ORAL
TOFRANIL-PM

	TYCO HLTHCARE	EQ 75MG HCL	N17090 001	MAR 15, 1973	JUN	CAHN
		EQ 100MG HCL	N17090 004	MAR 08, 1974	JUN	CAHN
		EQ 125MG HCL	N17090 003	MAR 08, 1974	JUN	CAHN
+		EQ 150MG HCL	N17090 002	MAR 15, 1973	JUN	CAHN

INDAPAMIDE
TABLET; ORAL
INDAPAMIDE

AB	GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN
AB		2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN

INDINAVIR SULFATE
CAPSULE; ORAL
CRIXIVAN

>A>	MERCK RES LABS	EQ 100MG BASE	N20685 006	APR 19, 2000	AUG	NEWA

IPRATROPIUM BROMIDE
SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN	ASLUNG PHARM	0.02%	N75693 001	JAN 26, 2001	JAN	NEWA
AN	NOVEX	0.02%	N75441 001	MAR 28, 2001	MAR	NEWA
AN	WARRICK PHARMS	0.02%	N75507 001	JAN 19, 2001	JAN	NEWA

ISOFLURANE
LIQUID; INHALATION
ISOFLURANE

AN	MINRAD	99.9%	N74416 001	SEP 30, 1994	FEB	CAHN

ISONIAZID
SYRUP; ORAL
ISONIAZID

+	CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983	MAY	CTEC
@	MIKART	50MG/5ML	N81118 001	JUL 21, 1997	MAY	DISC

TABLET; ORAL

@	HALSEY	100MG	N80136 001	NOV 13, 1970	MAY	DISC

ISOSORBIDE MONONITRATE
TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

>A>	AB	ZENITH GOLDLINE	30MG	N75448 002	AUG 07, 2001	AUG	NEWA
>A>	AB		120MG	N75448 003	AUG 07, 2001	AUG	NEWA

ISOTRETINOIN
CAPSULE; ORAL
ACCUTANE

+	HLR	20MG	N18662 004	MAR 28, 1983	APR	CTEC

KANAMYCIN SULFATE
INJECTABLE; INJECTION
KANAMYCIN SULFATE

@	LOCH	EQ 75MG BASE/2ML	N63021 001	JUL 31, 1992	MAY	DISC
@		EQ 500MG BASE/2ML	N63022 001	JUL 31, 1992	MAY	DISC
@		EQ 1GM BASE/3ML	N63025 001	JUL 31, 1992	APR	DISC
@	STERIS	EQ 1GM BASE/3ML	N62520 003	MAY 09, 1985	MAY	DISC

KANTREX

+	APOTHECON	EQ 75MG BASE/2ML	N61901 003	MAR 06, 1975	MAY	CTEC
+		EQ 500MG BASE/2ML	N61901 001	MAR 06, 1975	MAY	CTEC
+		EQ 1GM BASE/3ML	N61901 002	MAR 06, 1975	MAY	CTEC

KETOCONAZOLE
CREAM; TOPICAL
NIZORAL

AB +	JANSSEN	2%	N19084 001	DEC 31, 1985	JUL	CAHN

KETOROLAC TROMETHAMINE
INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	APOTEX	15MG/ML	N75631 002	JUN 29, 2001	JUN	NEWA
AP		30MG/ML	N75626 001	JUL 24, 2001	JUL	NEWA
AP		30MG/ML	N75631 001	JUN 29, 2001	JUN	NEWA
@	APOTHECON	15MG/ML	N75348 001	NOV 28, 2000	MAY	DISC
@		30MG/ML	N75348 002	NOV 28, 2000	MAY	DISC

LABETALOL HYDROCHLORIDE
INJECTABLE; INJECTION
LABETALOL HCL

@	APOTHECON	5MG/ML	N75355 001	NOV 29, 1999	MAY	DISC

TRANDATE

AP +	PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985	MAY	CAHN

LACTULOSE
SOLUTION; ORAL
LACTULOSE

AA	VINTAGE PHARMS	10GM/15ML	N75993 001	JUL 26, 2001	JUL	NEWA

LAMOTRIGINE
TABLET, CHEWABLE; ORAL
LAMICTAL CD

	GLAXO WELLCOME	2MG	N20764 004	SEP 08, 2000	MAR	NEWA

LANSOPRAZOLE
FOR SUSPENSION, EXTENDED RELEASE; ORAL
PREVACID

	TAP PHARM	15MG/PACKET	N21281 001	MAY 03, 2001	MAY	NEWA
+		30MG/PACKET	N21281 002	MAY 03, 2001	MAY	NEWA

LEUCOVORIN CALCIUM
INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001	JAN	NEWA

LEVOCARNITINE
INJECTABLE; INJECTION
CARNITOR

AP +	SIGMA TAU	200MG/ML	N20182 001	DEC 16, 1992	MAR	CFTG

LEVOCARNITINE

AP	BEDFORD	200MG/ML	N75567 001	MAR 29, 2001	MAR	NEWA
AP	GENSIA SICOR PHARMS	200MG/ML	N75881 001	MAR 29, 2001	MAR	NEWA
AP	LUITPOLD	200MG/ML	N75861 001	JUN 22, 2001	JUN	NEWA

LEVODOPA
CAPSULE; ORAL
DOPAR

	@ SHIRE LABS	250MG	N16913 001	JUN 04, 1970	MAY	DISC

TABLET; ORAL

	@ SHIRE LABS	250MG	N16913 004	JUL 06, 1972	JUN	DISC
	@	500MG	N16913 005	JUL 06, 1972	JUN	DISC

LARODOPA

	ROCHE	250MG	N16912 003	JUN 04, 1970	JUN	CRLD
+		500MG	N16912 004	JUN 04, 1970	JUN	CRLD

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
POLOCAINE W/ LEVONORDEFRIN

AP	DENTSPLY PHARM	0.05MG/ML;2%	N89517 001	APR 14, 1988	JUL	CAHN

LEVOTHYROXINE SODIUM
TABLET; ORAL
LEVOXYL

BX +	JONES PHARMA	0.025MG	N21301 001	MAY 25, 2001	MAY	NEWA
BX		0.025MG	N21301 001	MAY 25, 2001	JUL	CRLD
BX		0.05MG	N21301 002	MAY 25, 2001	MAY	NEWA
BX		0.075MG	N21301 003	MAY 25, 2001	MAY	NEWA
BX		0.088MG	N21301 004	MAY 25, 2001	MAY	NEWA
BX		0.1MG	N21301 005	MAY 25, 2001	MAY	NEWA
BX		0.112MG	N21301 006	MAY 25, 2001	MAY	NEWA
BX		0.125MG	N21301 007	MAY 25, 2001	MAY	NEWA
BX		0.137MG	N21301 008	MAY 25, 2001	MAY	NEWA
BX		0.15MG	N21301 009	MAY 25, 2001	MAY	NEWA
BX		0.175MG	N21301 010	MAY 25, 2001	MAY	NEWA
BX		0.2MG	N21301 011	MAY 25, 2001	MAY	NEWA
BX		0.3MG	N21301 012	MAY 25, 2001	MAY	NEWA
BX +		0.3MG	N21301 012	MAY 25, 2001	JUL	CRLD

UNITHROID

BX	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC
BX		0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
BX		0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
BX		0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC

	BX		0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
	BX		0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
	BX		0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
	BX		0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
	BX		0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
	BX		0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
	BX	+	0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC
		LIDOCAINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		LIDOCAINE HCL					
		@ STERIS	1%	N80377 001	FEB 20, 1974	JUL	DISC
		@	2%	N80377 002	FEB 20, 1974	JUL	DISC
		LIDOCATON					
		@ PHARMATON	2%	N84727 001	AUG 17, 1983	FEB	WDRP
		LINCOMYCIN HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		LINCOCIN					
		+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317 001	DEC 29, 1964	MAY	CTEC
		LINCOMYCIN HCL					
		@ STERIS	EQ 300MG BASE/ML	N63180 001	APR 16, 1991	MAY	DISC
		LISINOPRIL					
		TABLET; ORAL					
		ZESTRIL					
	AB	ASTRAZENECA	10MG	N19777 002	MAY 19, 1988	APR	CTEC
		LITHIUM CARBONATE					
		CAPSULE; ORAL					
		ESKALITH					
	AB	SMITHKLINE BEECHAM	300MG	N16860 001	APR 06, 1970	JUN	CRLD
		LITHIUM CARBONATE					
		+ ROXANE	600MG	N17812 003	JAN 28, 1987	JUN	CRLD
		LOPERAMIDE HYDROCHLORIDE					
		CAPSULE; ORAL					
		LOPERAMIDE HCL					
		@ ROXANE	2MG	N73080 001	NOV 27, 1991	JUL	DISC
		LORAZEPAM					
		TABLET; ORAL					
		LORAZEPAM					
>A>	AB	RANBAXY	0.5MG	N76045 001	AUG 29, 2001	AUG	NEWA
>A>	AB		1MG	N76045 002	AUG 29, 2001	AUG	NEWA
>A>	AB		2MG	N76045 003	AUG 29, 2001	AUG	NEWA
		@ WATSON LABS	0.5MG	N71086 001	MAR 23, 1987	JUL	DISC
		LOSARTAN POTASSIUM					
		TABLET; ORAL					
		COZAAR					
>D>		+ MERCK	50MG	N20386 002	APR 14, 1995	AUG	CRLD
>A>		MERCK RES LABS	50MG	N20386 002	APR 14, 1995	AUG	CRLD

>A>		+	100MG	N20386 003	OCT 13, 1998	AUG	NEWA

MECLIZINE HYDROCHLORIDE
TABLET; ORAL
MECLIZINE HCL

		@ CHELSEA LABS	12.5MG	N85269 001	NOV 11, 1976	MAY	DISC

MEGESTROL ACETATE
SUSPENSION; ORAL
MEGACE

AB	+	BRISTOL MYERS SQUIBB	40MG/ML	N20264 001	SEP 10, 1993	JUL	CFTG

MEGESTROL ACETATE

AB		PAR PHARM	40MG/ML	N75671 001	JUL 25, 2001	JUL	NEWA

MELOXICAM
TABLET; ORAL
MOBIC

		BOEHRINGER INGELHEIM	7.5MG	N20938 001	APR 13, 2000	JUL	CRLD
	+		15MG	N20938 002	AUG 23, 2000	JUL	NEWA

MEPERIDINE HYDROCHLORIDE
INJECTABLE; INJECTION
MEPERIDINE HCL

		@ ASTRAZENECA	50MG/ML	N89784 001	MAR 31, 1989	JUN	DISC
		@	100MG/ML	N89788 001	MAR 31, 1989	JUN	DISC

MEPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
MEPIVACAINE HCL

		@ INTL MEDICATION	1%	N87509 001	OCT 05, 1982	JUL	DISC

POLOCAINE

AP		DENTSPLY PHARM	3%	N88653 001	AUG 21, 1984	JUL	CAHN

MEPROBAMATE
TABLET; ORAL
AMOSENE

		@ FERNDALE LABS	400MG	N84030 001	MAY 10, 1974	FEB	WDRP

MEPROBAMATE

		@ HALSEY	400MG	N80699 002	OCT 16, 1972	MAY	DISC
>D>	AA	IMPAX LABS	200MG	N14322 002	JUL 23, 1973	AUG	DISC
>A>		@	200MG	N14322 002	JUL 23, 1973	AUG	DISC
>D>	AA		400MG	N14322 001	JUL 15, 1963	AUG	DISC
>A>		@	400MG	N14322 001	JUL 15, 1963	AUG	DISC

MEQUINOL; TRETINOIN
SOLUTION; TOPICAL
SOLAGE

	+	WESTWOOD SQUIBB	2%;0.01%	N20922 001	DEC 10, 1999	JUN	CAHN

MESALAMINE
SUPPOSITORY; RECTAL
CANASA

	+	AXCAN SCANDIPHARM	500MG	N21252 001	JAN 05, 2001	JAN	NEWA

MESNA
INJECTABLE; INTRAVENOUS
MESNA

AP		AM PHARM PARTNERS	100MG/ML	N75811 001	APR 26, 2001	APR	NEWA
AP		GENSIA SICOR PHARMS	100MG/ML	N75764 001	APR 27, 2001	APR	NEWA

MESNEX

AP	+	ASTA	100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG

METAPROTERENOL SULFATE
SOLUTION; INHALATION
METAPROTERENOL SULFATE

>D>	AN	ALPHARMA	0.4%	N71855 001	JUL 14, 1988	AUG	CAHN
>D>	AN		0.6%	N71726 001	JUL 14, 1988	AUG	CAHN
>A>	AN	NEPHRON	0.4%	N71855 001	JUL 14, 1988	AUG	CAHN
>A>	AN		0.6%	N71726 001	JUL 14, 1988	AUG	CAHN
	AN	NOVEX	0.4%	N75402 001	FEB 28, 2001	FEB	NEWA
	AN		0.6%	N75403 001	FEB 28, 2001	FEB	NEWA

METHAMPHETAMINE HYDROCHLORIDE
TABLET; ORAL
DESOXYN

	+	ABBOTT	5MG	N05378 002	DEC 31, 1943	JUL	CTEC

METHAMPHETAMINE HCL

	@	REXAR	5MG	N84931 001	JAN 19, 1976	JUL	DISC
	@		10MG	N84931 002	AUG 22, 1977	JUL	DISC

METHAZOLAMIDE
TABLET; ORAL
METHAZOLAMIDE

	@	APPLIED ANAL	25MG	N40011 001	JUL 17, 1997	MAY	DISC
	@		50MG	N40011 002	JUL 17, 1997	MAY	DISC

METHIMAZOLE
TABLET; ORAL
METHIMAZOLE

AB		EON	5MG	N40411 001	MAR 27, 2001	MAR	NEWA
AB			10MG	N40411 002	MAR 27, 2001	MAR	NEWA
	+	GENPHARM	20MG	N40350 003	JUN 07, 2001	JUN	NEWA

METHOTREXATE SODIUM
TABLET; ORAL
TREXALL

		BARR	EQ 5MG BASE	N40385 001	MAR 21, 2001	MAR	NEWA
			EQ 7.5MG BASE	N40385 002	MAR 21, 2001	MAR	NEWA
			EQ 10MG BASE	N40385 003	MAR 21, 2001	MAR	NEWA
	+		EQ 15MG BASE	N40385 004	MAR 21, 2001	MAR	NEWA

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
METHSCOPOLAMINE BROMIDE

	@	PVT FORM	2.5MG	N80970 001	OCT 18, 1976	MAY	DISC

PAMINE

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
PAMINE
+ BRADLEY PHARMS 2.5MG N08848 001 APR 09, 1953 MAY CTEC

METHYCLOTHIAZIDE
TABLET; ORAL
METHYCLOTHIAZIDE
@ PAR PHARM 2.5MG N89135 001 FEB 12, 1986 JUL DISC
@ 5MG N89136 001 FEB 12, 1986 JUL DISC

METHYLDOPA
TABLET; ORAL
METHYLDOPA
@ LEDERLE 125MG N70070 003 OCT 15, 1985 MAY DISC

METHYLPHENIDATE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD
+ CELLTECH PHARMS 20MG N21259 001 APR 03, 2001 APR NEWA
TABLET; ORAL
METHYLPHENIDATE HCL
AB ABLE 5MG N40404 001 MAR 29, 2001 MAR NEWA
AB 10MG N40404 002 MAR 29, 2001 MAR NEWA
AB 20MG N40404 003 MAR 29, 2001 MAR NEWA
TABLET, EXTENDED RELEASE; ORAL
METADATE ER
AB CELLTECH PHARMS 10MG N40306 001 OCT 20, 1999 APR CTEC
METHYLPHENIDATE HCL
AB ABLE 20MG N76032 001 MAY 09, 2001 MAY NEWA
AB DANBURY PHARMA 20MG N40410 001 FEB 09, 2001 FEB NEWA

METHYLPREDNISOLONE ACETATE
INJECTABLE; INJECTION
DEPO-MEDROL
PHARMACIA AND UPJOHN 40MG/ML N11757 001 APR 27, 1959 MAY CTEC
METHYLPREDNISOLONE ACETATE
@ STERIS 40MG/ML N85600 001 MAR 14, 1979 MAY DISC

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-MEDROL ACETATE
@ PHARMACIA AND UPJOHN 0.25%;EQ 3.5MG BASE/GM N60611 002 DEC 07, 1964 MAY DISC
@ 1%;EQ 3.5MG BASE/GM N60611 001 DEC 07, 1964 MAY DISC

METHYLPREDNISOLONE SODIUM SUCCINATE
INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE
@ GENSIA SICOR PHARMS EQ 500MG BASE/VIAL N81267 001 NOV 30, 1992 MAY DISC
@ EQ 1GM BASE/VIAL N81268 001 NOV 30, 1992 MAY DISC

		METHYLTESTOSTERONE						
		TABLET; BUCCAL						
		ORETON						
		@ SCHERING	10MG	N80281	001	AUG 03, 1979	FEB	DISC
		TABLET; BUCCAL/SUBLINGUAL						
		METHYLTESTOSTERONE						
		@ IMPAX LABS	10MG	N84287	001	JUL 16, 1974	JUL	DISC
		@ LILLY	10MG	N80256	001	DEC 22, 1971	JUL	DISC
		TABLET; ORAL						
		@ LILLY	25MG	N80256	002	DEC 22, 1971	JUL	DISC
		METIPRANOLOL HYDROCHLORIDE						
		SOLUTION/DROPS; OPHTHALMIC						
>A>		METIPRANOLOL						
>A>	AT	FALCON PHARMS	0.3%	N75720	001	AUG 06, 2001	AUG	NEWA
>A>		OPTIPRANOLOL						
>D>	+	BAUSCH AND LOMB	0.3%	N19907	001	DEC 29, 1989	AUG	CFTG
>A>	AT +		0.3%	N19907	001	DEC 29, 1989	AUG	CFTG
		METOCLOPRAMIDE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		METOCLOPRAMIDE HCL						
		@ ABBOTT	EQ 5MG BASE/ML	N70506	001	JUN 22, 1989	MAY	DISC
		SOLUTION; INJECTION						
		METOCLOPRAMIDE						
	AA	UDL	EQ 5MG BASE/5ML	N75051	001	JAN 26, 2001	JAN	NEWA
		SOLUTION; ORAL						
	AA	UDL	EQ 5MG BASE/5ML	N75051	001	JAN 26, 2001	MAY	CDFR
		TABLET; ORAL						
		METOCLOPRAMIDE HCL						
	AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478	001	OCT 05, 1995	JAN	CAHN
	AB		EQ 10MG BASE	N74478	002	OCT 05, 1995	JAN	CAHN
		@ MUTUAL PHARM	EQ 5MG BASE	N71536	002	JAN 16, 1997	JUL	DISC
		@	EQ 10MG BASE	N71536	001	APR 28, 1993	JUL	DISC
		METOPROLOL SUCCINATE						
		TABLET, EXTENDED RELEASE; ORAL						
		TOPROL-XL						
	+	ASTRAZENECA	EQ 25MG TARTRATE	N19962	004	FEB 05, 2001	FEB	NEWA
			EQ 25MG TARTRATE	N19962	004	FEB 05, 2001	JUL	CRLD
			EQ 100MG TARTRATE	N19962	002	JAN 10, 1992	JUL	CRLD
		METRONIDAZOLE						
		INJECTABLE; INJECTION						
		METRO I.V.						
		@ B BRAUN	500MG/100ML	N18674	001	AUG 31, 1982	MAY	DISC
		METRONIDAZOLE						
		@ ABBOTT	500MG/100ML	N18889	001	NOV 18, 1983	MAY	DISC
		@ ELKINS SINN	500MG/100ML	N18907	001	MAR 30, 1984	MAY	DISC
		TABLET; ORAL						
		PROTOSTAT						
		@ JOHNSON RW	250MG	N18871	001	MAR 02, 1983	MAR	DISC

@		500MG	N18871 002	MAR 02, 1983	MAR	DISC

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

@	BAYER	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983	MAY	DISC
@		EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982	MAY	DISC
@		EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982	MAY	DISC
@		EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982	MAY	DISC
@		EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988	MAY	DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HCL

@	APOTHECON	EQ 1MG BASE/ML	N75620 001	NOV 01, 2000	MAY	DISC
@		EQ 5MG BASE/ML	N75620 002	NOV 01, 2000	MAY	DISC
@		EQ 5MG BASE/ML	N75641 001	OCT 19, 2000	MAY	DISC
@	ASTRAZENECA	EQ 5MG BASE/ML	N75263 001	JUN 26, 2000	MAY	DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	LEDERLE	EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	NEWA
AB +		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CRLD

MINOCYCLINE HCL

AB	DANBURY PHARMA	EQ 100MG BASE	N63065 001	DEC 30, 1991	MAR	CRLD
AB	IMPAX LABS	EQ 75MG BASE	N65005 003	APR 18, 2001	APR	NEWA

VECTRIN

@	MEDICIS	EQ 75MG BASE	N63067 002	SEP 15, 1999	MAY	DISC
@		EQ 100MG BASE	N63067 001	JUL 31, 1990	MAY	DISC

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+	ORAPHARMA	EQ 1MG BASE	N50781 001	FEB 16, 2001	FEB	NEWA

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

REMERON SOLTAB

+	ORGANON INC	15MG	N21208 001	JAN 12, 2001	JAN	NEWA
		30MG	N21208 002	JAN 12, 2001	JAN	NEWA
		45MG	N21208 003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+	FAULDING PHARMS	20MG	N20616 001	JUL 03, 1996	JUN	CAHN
+		30MG	N20616 004	MAR 09, 2001	JUN	NEWA
+		50MG	N20616 002	JUL 03, 1996	JUN	CAHN
+		60MG	N20616 005	MAR 09, 2001	JUN	NEWA
+		100MG	N20616 003	JUL 03, 1996	JUN	CAHN

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB	WATSON LABS	100MG	N75656 001	JAN 30, 2001	JAN	NEWA

NADOLOL
TABLET; ORAL
CORGARD

>D>	AB	+	APOTHECON	40MG	N18063 001	DEC 10, 1979	AUG	CRLD
>A>	AB			40MG	N18063 001	DEC 10, 1979	AUG	CRLD
			NADOLOL					
	AB		GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN
	AB			40MG	N74501 002	NOV 09, 1995	JAN	CAHN
	AB			80MG	N74501 003	NOV 09, 1995	JAN	CAHN

NAFCILLIN SODIUM
INJECTABLE; INJECTION
NAFCILLIN SODIUM

@	APOTHECON	EQ 500MG BASE/VIAL	N61984 001	APR 29, 1976	MAY	DISC
+		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984	MAY	CRLD
@		EQ 1GM BASE/VIAL	N61984 002	APR 29, 1976	MAY	DISC
@		EQ 2GM BASE/VIAL	N61984 003	APR 29, 1976	MAY	DISC
@		EQ 4GM BASE/VIAL	N61984 005	APR 29, 1976	MAY	DISC
@	MARSAM	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988	MAY	DISC
@		EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988	MAY	DISN
@		EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988	MAY	DISC
@		EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988	MAY	DISC
@		EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988	MAY	DISC
@		EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988	MAY	DISC
	NALLPEN					
@	SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61999 001	JUL 10, 1978	MAY	DISC
@		EQ 1GM BASE/VIAL	N61999 002	JUL 10, 1978	MAY	DISC
@		EQ 2GM BASE/VIAL	N61999 003	JUL 10, 1978	MAY	DISC
@		EQ 10GM BASE/VIAL	N61999 004	JUL 17, 1978	MAY	DISC
	UNIPEN					
@	WYETH AYERST	EQ 500MG BASE/VIAL	N50320 001	JUN 23, 1970	MAY	DISC
@		EQ 500MG BASE/VIAL	N62717 001	DEC 16, 1986	MAY	DISC
@		EQ 1GM BASE/VIAL	N62717 002	DEC 16, 1986	MAY	DISC
@		EQ 2GM BASE/VIAL	N50320 003	JUN 23, 1970	MAY	DISC
@		EQ 2GM BASE/VIAL	N62717 004	DEC 16, 1986	MAY	DISC
@		EQ 4GM BASE/VIAL	N50320 004	JUN 23, 1970	MAY	DISC
@		EQ 10GM BASE/VIAL	N50320 005	DEC 21, 1978	MAY	DISC
	UNIPEN IN PLASTIC CONTAINER					
@	WYETH AYERST	EQ 1GM BASE/VIAL	N50320 002	JUN 23, 1970	MAY	DISC

NALBUPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
NALBUPHINE HCL

@	ASTRAZENECA	10MG/ML	N72070 001	APR 10, 1989	JUN	DISC
@		20MG/ML	N72073 001	APR 10, 1989	JUN	DISC

NALOXONE HYDROCHLORIDE
INJECTABLE; INJECTION
NALOXONE

@	WYETH AYERST	0.02MG/ML	N70188 001	SEP 24, 1986	JAN	DISC
@		0.02MG/ML	N70189 001	SEP 24, 1986	JAN	DISC
@		0.4MG/ML	N70190 001	SEP 24, 1986	JAN	DISC

		@	0.4MG/ML	N70191 001	SEP 24, 1986	JAN	DISC	

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HCL AND PENTAZOCAINE

	AB		AMIDE PHARM	EQ 0.5MG BASE;EQ 50MG BASE	N75735 001	JUL 11, 2001	JUL	NEWA

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

>D>	AT		ALLERGAN	0.1%	N80248 001	MAR 24, 1972	AUG	CRLD
>A>	AT	+		0.1%	N80248 001	MAR 24, 1972	AUG	CRLD
	AT			0.1%	N80248 001	MAR 24, 1972	JUL	CRLD

NAPHCON FORTE

		@	ALCON	0.1%	N80229 001	MAR 06, 1974	JUL	DISC

OPCON

		@	BAUSCH AND LOMB	0.1%	N87506 001	DEC 01, 1981	JUL	DISC

VASOCON

	AT		NOVARTIS	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN

NAPROXEN

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN

	AB	+	ALPHAPHARM	375MG	N75390 001	APR 19, 2001	APR	NEWA
	AB	+		500MG	N75390 002	APR 19, 2001	APR	NEWA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

	AB		GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994	JAN	CAHN
	AB			EQ 500MG BASE	N74495 002	DEC 05, 1994	JAN	CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

SERZONE

			BRISTOL MYERS SQUIBB	50MG	N20152 001	DEC 22, 1994	APR	CTEC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATES

		@	STERIS	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664 001	APR 08, 1986	MAY	DISC

NEOSPORIN G.U. IRRIGANT

			MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001	JUN 28, 1966	MAY	CTEC

SOLUTION/DROPS; OPHTHALMIC

STATROL

		@	ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N62339 001	NOV 30, 1984	JUL	DISC

>A>	NESIRITIDE						
>A>	FOR SOLUTION; INTRAVENOUS						
>A>	NATRECOR						
>A>	+ SCIOS	1.5MG/VIAL	N20920 001	AUG 10, 2001	AUG	NEWA	
	NETILMICIN SULFATE						
	INJECTABLE; INJECTION						
	NETROMYCIN						
	@ SCHERING	EQ 100MG BASE/ML	N50544 003	FEB 28, 1983	MAY	DISC	
	NIFEDIPINE						
	CAPSULE; ORAL						
	NIFEDIPINE						
	@ CHASE LABS NJ	10MG	N72409 001	JUL 04, 1990	FEB	WDRP	
	@	20MG	N73421 001	JUN 19, 1991	FEB	WDRP	
	TABLET, EXTENDED RELEASE; ORAL						
	ADALAT CC						
AB1	BAYER	30MG	N20198 001	APR 21, 1993	APR	CTEC	
	NIFEDIPINE						
AB2	BIOVAIL	30MG	N75289 002	FEB 06, 2001	FEB	NEWA	
	PROCARDIA XL						
AB2 +	PFIZER	30MG	N19684 001	SEP 06, 1989	FEB	CTEC	
	NITROFURAZONE						
	OINTMENT; TOPICAL						
	NITROFURAZONE						
	@ CLAY PARK	0.2%	N84968 001	JAN 25, 1978	MAY	DISC	
	POWDER; TOPICAL						
	FURACIN						
	@ ROBERTS LABS	0.2%	N83791 001	OCT 17, 1975	FEB	WDRP	
	SOLUTION; TOPICAL						
	NITROFURAZONE						
	@ CLAY PARK	0.2%	N85130 001	NOV 02, 1978	MAY	DISC	
	+ WENDT	0.2%	N87081 001	JUL 22, 1981	MAY	CTEC	
	NITROGLYCERIN						
	AEROSOL; SUBLINGUAL						
	NITROLINGUAL						
	@ POHL BOSKAMP	0.4MG/SPRAY	N18705 001	OCT 31, 1985	APR	DISC	
	NORETHINDRONE ACETATE						
	TABLET; ORAL						
	NORETHINDRONE ACETATE						
AB	BARR	5MG	N75951 001	MAY 25, 2001	MAY	NEWA	
	NORTRIPTYLINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	PAMELOR						
AB	TYCO HLTHCARE	EQ 10MG BASE	N18013 001	AUG 01, 1977	JUN	CAHN	
AB		EQ 25MG BASE	N18013 002	AUG 01, 1977	JUN	CAHN	
AB		EQ 50MG BASE	N18013 004	JUN 14, 1979	JUN	CAHN	
AB +		EQ 75MG BASE	N18013 003	JUN 14, 1979	JUN	CAHN	

NORTRIPTYLINE HYDROCHLORIDE
SOLUTION; ORAL
PAMELOR
SOLUTION; ORAL

AA	TYCO HLTHCARE	EQ 10MG BASE/5ML	N18012 001	AUG 01, 1977	JUN	CAHN

NYSTATIN
CREAM; TOPICAL
NILSTAT

	@ LEDERLE	100,000 UNITS/GM	N61445 001	APR 02, 1971	MAY	DISC

NYSTATIN

	@ TEVA	100,000 UNITS/GM	N61966 001	MAY 25, 1976	MAY	DISC

OINTMENT; TOPICAL
NILSTAT

	@ LEDERLE	100,000 UNITS/GM	N61444 001	MAR 29, 1971	MAY	DISC

NYSTATIN

AT	+ ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982	MAY	CTEC

SUSPENSION; ORAL

	@ ROXANE	100,000 UNITS/ML	N62832 001	DEC 27, 1991	MAY	DISC
	@ TEVA	100,000 UNITS/ML	N62670 001	JUN 18, 1987	MAY	DISC
	@	100,000 UNITS/ML	N62776 001	DEC 17, 1987	MAY	DISC
	@ THAMES	100,000 UNITS/ML	N62876 001	FEB 29, 1988	JUL	DISC

TABLET; ORAL

	@ EON	500,000 UNITS	N62065 001	JUL 22, 1977	MAY	DISC
	@ ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985	MAY	DISC

TABLET; VAGINAL
KOROSTATIN

	@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP

NYSTATIN; TRIAMCINOLONE ACETONIDE
OINTMENT; TOPICAL
MYCO-TRIACET II

	@ TEVA	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985	MAY	DISC

NYSTATIN AND TRIAMCINOLONE ACETONIDE

	@ CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985	MAY	DISC

OLANZAPINE
TABLET; ORAL
ZYPREXA

	LILLY	15MG	N20592 005	SEP 09, 1997	JUN	CRLD
	+	20MG	N20592 006	SEP 09, 1997	JUN	CMFD

OXACILLIN SODIUM
INJECTABLE; INJECTION
BACTOCILL

	@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC
	@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC

OXACILLIN SODIUM

AP	+ APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD
AP	+	EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD
	@ IBI	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC
	@	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC
	@	EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC

	@	EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC	
	OXAPROZIN						
	TABLET; ORAL						
	DAYPRO						
AB	+ SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG	
	OXAPROZIN						
AB	DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA	
AB	EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA	
AB	GENEVA PHARMS	600MG	N75850 001	APR 27, 2001	APR	NEWA	
AB	GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA	
AB	INVAMED	600MG	N75842 001	APR 12, 2001	APR	NEWA	
>A> AB	MYLAN	600MG	N75851 001	AUG 17, 2001	AUG	NEWA	
AB	WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA	
	OXAZEPAM						
	CAPSULE; ORAL						
	SERAX						
AB	FAULDING PHARMS	10MG	N15539 002	SEP 29, 1966	JUN	CAHN	
AB		15MG	N15539 004	SEP 29, 1966	JUN	CAHN	
AB +		30MG	N15539 006	SEP 29, 1966	JUN	CAHN	
	TABLET; ORAL						
	+ FAULDING PHARMS	15MG	N15539 008	NOV 16, 1967	JUN	CAHN	
	OXCARBAZEPINE						
	SUSPENSION; ORAL						
	TRILEPTAL						
	+ NOVARTIS	300MG/5ML	N21285 001	MAY 25, 2001	MAY	NEWA	
	OXYCODONE HYDROCHLORIDE						
	TABLET, EXTENDED RELEASE; ORAL						
	OXYCONTIN						
	@ PURDUE PHARMA LP	160MG	N20553 005	MAR 15, 2000	JUN	DISC	
	OXYTETRACYCLINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	OXYTETRACYCLINE HCL						
	@ IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC	
	@ PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP	
	@ WEST WARD	EQ 250MG BASE	N60770 001	SEP 29, 1967	MAY	DISC	
	TERRAMYCIN						
	+ PFIZER	EQ 250MG BASE	N50286 002	SEP 08, 1964	MAY	CTEC	
	PACLITAXEL						
	INJECTABLE; INJECTION						
	PACLITAXEL						
AP	BEDFORD	6MG/ML	N75190 001	JUL 27, 2001	JUL	NEWA	
AP	MYLAN	6MG/ML	N75278 001	JUL 23, 2001	JUL	NEWA	
AP	ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA	

PAMIDRONATE DISODIUM							
INJECTABLE; INJECTION							
AREDIA							
AP + NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG		
AP +	90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG		
PAMIDRONATE DISODIUM							
AP BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA		
AP	90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA		
PANCURONIUM BROMIDE							
INJECTABLE; INJECTION							
PANCURONIUM BROMIDE							
@ ASTRAZENECA	1MG/ML	N72210 001	MAR 31, 1988	JUL	DISC		
@	2MG/ML	N72211 001	MAR 31, 1988	JUL	DISC		
@	2MG/ML	N72213 001	MAR 31, 1988	JUL	DISC		
PANTOPRAZOLE SODIUM							
INJECTABLE; IV (INFUSION)							
PROTONIX IV							
+ WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	NEWA		
TABLET, DELAYED RELEASE; ORAL							
PROTONIX							
+ WYETH AYERST	EQ 20MG BASE	N20987 002	JUN 12, 2001	JUN	NEWA		
PEMOLINE							
TABLET; ORAL							
PEMOLINE							
AB MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001	MAR	NEWA		
AB	37.5MG	N75726 002	MAR 30, 2001	MAR	NEWA		
AB	75MG	N75726 001	MAR 30, 2001	MAR	NEWA		
AB WATSON LABS	18.75MG	N75287 001	JUN 13, 2001	JUN	NEWA		
PENCICLOVIR SODIUM							
CREAM; TOPICAL							
DENAVIR							
+ NOVARTIS	1%	N20629 001	SEP 24, 1996	JUL	CAHN		
PENICILLIN G POTASSIUM							
FOR SOLUTION; ORAL							
PENICILLIN							
@ TEVA	200,000 UNITS/5ML	N60307 002	MAY 27, 1964	JUL	DISC		
@	400,000 UNITS/5ML	N60307 004	MAY 27, 1964	JUL	DISC		
PENICILLIN-2							
@ TEVA	250,000 UNITS/5ML	N60307 003	MAY 27, 1964	JUL	DISC		
TABLET; ORAL							
PENICILLIN G POTASSIUM							
@ TEVA	200,000 UNITS	N60306 001	JUN 01, 1964	MAY	DISC		
@	250,000 UNITS	N60306 002	JUN 01, 1964	MAY	DISC		
@	400,000 UNITS	N60306 003	JUN 01, 1964	MAY	DISC		
@	500,000 UNITS	N60306 004	JUN 26, 1979	MAY	DISC		

PENICILLIN G PROCAINE
INJECTABLE; INJECTION
PENICILLIN G PROCAINE

@ PFIZER	300,000 UNITS/VIAL	N60099 001	NOV 10, 1948	MAY	DISC
@	1,500,000 UNITS/VIAL	N60099 002	NOV 10, 1948	MAY	DISC

PFIZERPEN-AS

@ PFIZER	300,000 UNITS/ML	N60286 001	NOV 01, 1950	MAY	DISC
@	600,000 UNITS/ML	N60286 002	NOV 01, 1950	MAY	DISC

WYCILLIN

+ KING PHARMS	300,000 UNITS/ML	N60101 002	APR 26, 1948	MAY	CTEC
+	600,000 UNITS/ML	N60101 001	APR 26, 1948	MAY	CTEC

PENICILLIN G SODIUM
INJECTABLE; IM-IV
PENICILLIN G SODIUM

+ BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	FEB 26, 2001	FEB	NEWA
@ MARSAM	5,000,000 UNITS/VIAL	N63014 001	SEP 13, 1988	FEB	DISC

PENICILLIN V POTASSIUM
FOR SOLUTION; ORAL
PENICILLIN V POTASSIUM

@ MYLAN	EQ 125MG BASE/5ML	N61624 002	AUG 07, 1972	MAY	DISC
@	EQ 250MG BASE/5ML	N61624 001	JUN 05, 1972	MAY	DISC

V-CILLIN K

@ LILLY	EQ 125MG BASE/5ML	N60004 001	AUG 21, 1958	MAY	DISC
@	EQ 250MG BASE/5ML	N60004 002	APR 07, 1967	MAY	DISC

TABLET; ORAL
PEN-VEE K

AB + WYETH AYERST	EQ 500MG BASE	N60006 003	JAN 13, 1958	MAY	CRLD

PENICILLIN V POTASSIUM

AB + BIOCHEMIE	EQ 500MG BASE	N64071 002	NOV 30, 1995	MAY	CTEC
@ MYLAN	EQ 250MG BASE	N61530 001	NOV 18, 1971	MAY	DISC
@	EQ 500MG BASE	N61530 002	MAR 20, 1972	MAY	DISC

V-CILLIN K

@ LILLY	EQ 125MG BASE	N60003 001	SEP 17, 1957	MAY	DISC
@	EQ 250MG BASE	N60003 002	SEP 17, 1957	MAY	DISC
@	EQ 500MG BASE	N60003 003	SEP 17, 1957	MAY	DISC

PENTOBARBITAL
ELIXIR; ORAL
NEMBUTAL

@ ABBOTT	18.2MG/5ML	N83244 001	JAN 08, 1975	JUL	DISC

PENTOBARBITAL SODIUM
CAPSULE; ORAL
NEMBUTAL SODIUM

@ ABBOTT	50MG	N84093 001	JAN 14, 1975	JUL	DISC

SUPPOSITORY; RECTAL
NEMBUTAL

@ ABBOTT	30MG	N83247 001	JAN 25, 1982	JUL	DISC
@	60MG	N83247 002	JAN 25, 1982	JUL	DISC
@	120MG	N83247 003	JAN 25, 1982	JUL	DISC

	@	200MG	N83247 004	JAN 25, 1982	JUL	DISC

PERFLUTREN
INJECTABLE; INTRAVENOUS
DEFINITY

	+ DUPONT PHARMS	6.52MG/ML	N21064 001	JUL 31, 2001	JUL	NEWA

PERPHENAZINE
CONCENTRATE; ORAL
PERPHENAZINE

	+ PHARM ASSOC	16MG/5ML	N40360 001	MAY 25, 2001	MAY	NEWA

TRILAFON

	@ SCHERING	16MG/5ML	N11557 001	DEC 12, 1958	MAR	DISC

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM
TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL

	+ ABLE	200MG;800MG;160MG	N21105 001	JUN 26, 2001	JUN	NEWA

PHENDIMETRAZINE TARTRATE
CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE

	@ EON	35MG	N85633 001	JUL 13, 1978	JUL	DISC
	@	35MG	N85694 001	JUN 05, 1978	MAY	DISC
AA	+	35MG	N85695 001	JUN 05, 1978	JUL	CRLD
	@	35MG	N85702 001	JUN 07, 1978	JUL	DISC

CAPSULE, EXTENDED RELEASE; ORAL

BC	+ EON	105MG	N18074 001	APR 16, 1979	JUL	CRLD
	@ GENEVA PHARMS	105MG	N87378 001	NOV 03, 1981	JUL	DISC

TABLET; ORAL
PHENAZINE-35

	@ ABC HOLDING	35MG	N85512 001	MAY 06, 1977	MAY	DISC

PHENDIMETRAZINE TARTRATE

	@ EON	35MG	N85402 001	MAY 19, 1978	MAY	DISC
	@	35MG	N85497 001	AUG 19, 1977	MAY	DISC
	@ MIKART	35MG	N89452 001	OCT 30, 1991	JUL	DISC
	@ ROSEMONT	35MG	N84399 001	MAY 28, 1981	MAY	DISC

STATOBEX

	@ TEVA	35MG	N86013 001	DEC 16, 1977	JUL	DISC

X-TROZINE

	@ SHIRE RICHWOOD	35MG	N86550 001	SEP 16, 1981	JUL	DISC
	@	35MG	N86551 001	SEP 16, 1981	JUL	DISC
	@	35MG	N86552 001	SEP 16, 1981	JUL	DISC

PHENTERMINE HYDROCHLORIDE
CAPSULE; ORAL
OBY-TRIM

	@ SHIRE RICHWOOD	30MG	N87764 001	MAR 18, 1982	JUL	DISC

PHENTERMINE HCL

	@ ABC HOLDING	30MG	N85411 001	SEP 10, 1980	MAY	DISC
>A>	AA ABLE	30MG	N40403 001	AUG 30, 2001	AUG	NEWA
>A>	AA	30MG	N40427 001	AUG 30, 2001	AUG	NEWA
	@ ROSEMONT	30MG	N84487 001	APR 09, 1982	MAY	DISC

PHENTERMINE HYDROCHLORIDE
TABLET; ORAL
PHENTERMINE HCL
TABLET; ORAL

>A>	AA	ABLE	37.5MG	N40402 001	AUG 30, 2001	AUG	NEWA
	+	EON	30MG	N88605 001	SEP 28, 1987	MAY	CMFD

PHENYTOIN
SUSPENSION; ORAL
PHENYTOIN

	AB	UDL	125MG/5ML	N40342 001	JAN 31, 2001	JAN	NEWA

PIPERAZINE CITRATE
SYRUP; ORAL
PIPERAZINE CITRATE

		@ LANNETT	EQ 500MG BASE/5ML	N80963 001	JUL 25, 1974	MAY	DISC

TABLET; ORAL

		@ IMPAX LABS	EQ 250MG BASE	N80874 001	JUL 19, 1973	MAY	DISC

PIPOBROMAN
TABLET; ORAL
VERCYTE

		@ ABBOTT	25MG	N16245 002	JUL 01, 1966	JUL	DISC

POTASSIUM CHLORIDE
TABLET, EXTENDED RELEASE; ORAL
K-DUR 10

	AB	KEY PHARMS	10MEQ	N19439 002	JUN 13, 1986	APR	CTEC

PRAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
PRAZOSIN HCL

		@ PUREPAC PHARM	EQ 1MG BASE	N72991 001	MAY 16, 1989	JUL	DISC
		@	EQ 2MG BASE	N72921 001	MAY 16, 1989	JUL	DISC
		@	EQ 5MG BASE	N72992 001	MAY 16, 1989	JUL	DISC

PREDNICARBATE
OINTMENT; TOPICAL
DERMATOP

	+	AVENTIS PHARMS	0.1%	N19568 001	SEP 23, 1991	MAR	CMFD

PREDNISOLONE
TABLET; ORAL
PREDNISOLONE

		@ CHELSEA LABS	5MG	N85085 002	FEB 23, 1977	MAY	DISC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
VASOCIDIN

	AT	NOVARTIS	0.5%;10%	N88791 001	OCT 05, 1984	FEB	CAHN

SUSPENSION/DROPS; OPHTHALMIC
METIMYD

	+	SCHERING	0.5%;10%	N10210 001	FEB 24, 1956	FEB	CTEC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

		PREDAMIDE					
		@ AKORN	0.5%;10%	N88059 001	JUL 29, 1983	FEB	WDRP
		SULPHRIN					
		@ BAUSCH AND LOMB	0.5%;10%	N88089 001	DEC 28, 1982	FEB	WDRP

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

		INFLAMASE FORTE					
AT	+	NOVARTIS	EQ 0.9% PHOSPHATE	N80751 002	DEC 19, 1973	FEB	CAHN
		INFLAMASE MILD					
AT	+	NOVARTIS	EQ 0.11% PHOSPHATE	N80751 001	DEC 19, 1973	FEB	CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
		@ AKORN	EQ 0.11% PHOSPHATE	N83358 001	AUG 21, 1974	FEB	WDRP
		@	EQ 0.9% PHOSPHATE	N83358 002	AUG 21, 1974	FEB	WDRP
		@ ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043 001	OCT 24, 1991	MAY	DISC
		@	EQ 0.9% PHOSPHATE	N81044 001	OCT 24, 1991	MAY	DISC

PREDNISONE

TABLET; ORAL

		PREDNISONE					
		@ CHELSEA LABS	5MG	N85084 002	DEC 15, 1981	MAY	DISC
		@ GENEVA PHARMS	5MG	N80336 002	JUL 29, 1976	MAY	DISC
		@ HALSEY	10MG	N86595 001	APR 10, 1979	JUL	DISC
		@ LANNETT	20MG	N84275 001	JUN 27, 1974	MAY	DISC
>A>	AB	TRIGEN	5MG	N40362 002	AUG 29, 2001	AUG	NEWA
>A>	AB		10MG	N40362 001	AUG 29, 2001	AUG	NEWA

PRIMIDONE

SUSPENSION; ORAL

		MYSOLINE					
	+	XCEL PHARMS	250MG/5ML	N10401 001	JUL 05, 1956	JUL	CAHN

TABLET; ORAL

AB		ELAN PHARMA	50MG	N09170 003	MAR 08, 1954	MAY	CFTG
AB		XCEL PHARMS	50MG	N09170 003	MAR 08, 1954	JUL	CAHN
AB	+		250MG	N09170 002	MAR 08, 1954	JUL	CAHN
		PRIMIDONE					
AB		LANNETT	50MG	N84903 002	MAY 24, 2001	MAY	NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

		COMPAZINE					
AB		SMITHKLINE BEECHAM	2.5MG	N11127 003	FEB 09, 1959	JUL	CFTG
AB			5MG	N11127 001	SEP 27, 1957	JUL	CFTG
		PROCHLORPERAZINE					
AB		ABLE	2.5MG	N40407 001	JUL 11, 2001	JUL	NEWA
AB			5MG	N40407 002	JUL 11, 2001	JUL	NEWA
AB			25MG	N40407 003	JUL 11, 2001	JUL	NEWA

PROCHLORPERAZINE EDISYLATE
INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE
@ WYETH AYERST — EQ 5MG BASE/ML — N86348 001 JUL 05, 1979 JUL DISC

PROCHLORPERAZINE MALEATE
TABLET; ORAL
PROCHLORPERAZINE MALEATE
AB GENEVA PHARMS TECH — EQ 5MG BASE — N40101 001 JUL 19, 1996 JAN CAHN
AB — EQ 10MG BASE — N40101 002 JUL 19, 1996 JAN CAHN
AB — EQ 25MG BASE — N40101 003 JUL 19, 1996 JAN CAHN

PROGESTERONE
INJECTABLE; INJECTION
PROGESTERONE
AO AM PHARM PARTNERS — 50MG/ML — N75906 001 APR 25, 2001 APR NEWA
AO + STERIS — 50MG/ML — N17362 002 MAY 08, 1978 APR CFTG

PROMETHAZINE HYDROCHLORIDE
SUPPOSITORY; RECTAL
PROMETHACON
@ POLYMEDICA — 50MG — N84902 001 OCT 05, 1981 MAY DISC
TABLET; ORAL
PHENERGAN
WYETH AYERST — 12.5MG — N07935 002 MAR 29, 1951 MAY CTEC
PROMETHAZINE HCL
@ LANNETT — 12.5MG — N80949 001 JUL 28, 1976 MAY DISC
@ — 25MG — N80949 002 JUN 28, 1976 MAY DISC
@ — 50MG — N80949 003 JUN 28, 1976 MAY DISC
@ PVT FORM — 25MG — N83658 001 OCT 01, 1976 MAY DISC

PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
PROPOXYPHENE HCL
@ GENEVA PHARMS — 65MG — N83125 002 APR 14, 1976 MAY DISC
@ IMPAX LABS — 65MG — N83317 001 OCT 23, 1973 MAY DISC

PROPRANOLOL HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
INDERAL LA
>D> + WYETH AYERST — 60MG — N18553 004 MAR 18, 1987 AUG CRLD
>D> + — 80MG — N18553 002 APR 19, 1983 AUG CRLD
>D> + — 120MG — N18553 003 APR 19, 1983 AUG CRLD
>A> WYETH AYERST LABS — 60MG — N18553 004 MAR 18, 1987 AUG CRLD
>A> — 80MG — N18553 002 APR 19, 1983 AUG CRLD
>A> — 120MG — N18553 003 APR 19, 1983 AUG CRLD
TABLET; ORAL
PROPRANOLOL HCL
@ LEDERLE — 10MG — N70125 001 JUL 30, 1985 MAY DISC
@ WATSON LABS — 20MG — N70549 001 APR 11, 1986 MAY DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HCL

AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	JAN	CAHN
AB		10MG	N73645 001	AUG 24, 1995	JAN	CAHN

VIVACTIL

AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	MAR	CTNA
AB +		10MG	N73645 001	AUG 24, 1995	MAR	CTNA
@	SIDMAK LABS	5MG	N16012 001	SEP 27, 1967	MAR	DISC
@		10MG	N16012 002	SEP 27, 1967	MAR	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRILITRON

@	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474 001	FEB 12, 1985	FEB	WDRP

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINAGLUTE

BX +	BERLEX LABS	324MG	N16647 001	DEC 08, 1969	MAR	CTEC

QUINIDINE GLUCONATE

BX	DANBURY PHARMA	324MG	N87810 001	SEP 29, 1982	MAR	CTEC
@	GENEVA PHARMS	324MG	N89894 001	DEC 15, 1988	MAR	DISC
BX	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	MAR	CTEC

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@	IMPAX LABS	200MG	N83347 001	DEC 08, 1976	FEB	DISC
@	MUTUAL PHARM	300MG	N81031 001	APR 14, 1989	MAY	DISC
@	WEST WARD	200MG	N83862 001	SEP 02, 1976	MAY	DISC

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANTAC 150

>D> AB	GLAXO WELLCOME	EQ 150MG BASE	N20095 001	MAR 08, 1994	AUG	DISC
>A> @		EQ 150MG BASE	N20095 001	MAR 08, 1994	AUG	DISC

RIBAVIRIN

CAPSULE; ORAL

REBETOL

>A> +	SCHERING PLOUGH RES	200MG	N20903 002	JUL 25, 2001	AUG	NEWA

RIFAMPIN

CAPSULE; ORAL

RIFAMPIN

AB	VERSAPHARM	150MG	N65028 001	MAR 14, 2001	MAR	NEWA
AB		300MG	N65028 002	MAR 14, 2001	MAR	NEWA

RISPERIDONE
TABLET; ORAL
RISPERDAL
JANSSEN

+	0.5MG	N20272 007	JAN 27, 1999	APR	CRLD
	1MG	N20272 001	DEC 29, 1993	APR	CRLD
	4MG	N20272 004	DEC 29, 1993	APR	CRLD

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECOBARBITAL SODIUM

@ ICN	100MG	N85477 001	DEC 10, 1981	FEB	WDRP

SECRETIN
INJECTABLE; INJECTION
SECRETIN-FERRING

@ FERRING	75CU/VIAL	N18290 001	MAY 29, 1981	JUN	DISC

SILVER SULFADIAZINE
DRESSING; TOPICAL
SILDAFLO

@ QUESTCOR PHARMS	1%	N19608 001	NOV 30, 1989	MAY	CTNA

SIMVASTATIN
TABLET; ORAL
ZOCOR
MERCK

5MG	N19766 001	DEC 23, 1991	APR	CTEC

SODIUM POLYSTYRENE SULFONATE
SUSPENSION; ORAL, RECTAL
SPS

AA	+	CAROLINA MEDCL	15GM/60ML	N87859 001	DEC 08, 1982	MAY	CRLD

SODIUM TETRADECYL SULFATE
INJECTABLE; INJECTION
SOTRADECOL

@ ELKINS SINN	1%	N05970 004	AUG 13, 1946	JUL	DISC
@	3%	N05970 005	AUG 13, 1946	JUL	DISC

SOMATROPIN RECOMBINANT
INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
SAIZEN

>A>	+	SERONO	8.8MG/VIAL	N19764 003	AUG 29, 2000	AUG	NEWA

SOTALOL HYDROCHLORIDE
TABLET; ORAL
SORINE

AB		UPSHER SMITH	80MG	N75500 001	APR 27, 2001	APR	NEWA
AB			120MG	N75500 004	APR 27, 2001	APR	NEWA
AB			160MG	N75500 002	APR 27, 2001	APR	NEWA
AB			240MG	N75500 003	APR 27, 2001	APR	NEWA

SPIRONOLACTONE
TABLET; ORAL
SPIRONOLACTONE

>A>	AB	MYLAN	25MG	N40424 001	AUG 20, 2001	AUG	NEWA
>A>	AB		50MG	N40424 002	AUG 20, 2001	AUG	NEWA
>A>	AB		100MG	N40424 003	AUG 20, 2001	AUG	NEWA

STREPTOMYCIN SULFATE
INJECTABLE; INJECTION
STREPTOMYCIN SULFATE

		@ PFIZER	EQ 1GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC
		@	EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC
	+	PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC

SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
BLEPH-10

		@ ALLERGAN	10%	N84015 001	JAN 07, 1975	MAY	DISC

CETAMIDE

AT	+	ALCON	10%	N80021 001	SEP 27, 1972	MAY	CTEC

SODIUM SULAMYD

		@ SCHERING	10%	N05963 002	NOV 26, 1947	MAY	DISC

SOLUTION/DROPS; OPHTHALMIC
BLEPH-10

AT	+	ALLERGAN	10%	N80028 001	MAY 25, 1971	MAY	CRLD

BLEPH-30

AT	+	ALLERGAN	30%	N80028 002	MAY 25, 1971	MAY	CRLD

SODIUM SULAMYD

		@ SCHERING	10%	N05963 001	AUG 01, 1946	MAY	DISC
		@	30%	N05963 003	NOV 26, 1947	MAY	DISC

SULF-10

		@ NOVARTIS	10%	N80025 001	JUN 03, 1971	FEB	CAHN

SULF-15

AT		NOVARTIS	15%	N89047 001	OCT 31, 1995	FEB	CAHN

SULTEN-10

		@ BAUSCH AND LOMB	10%	N87818 001	FEB 03, 1983	FEB	WDRP

SULFAMETHOXAZOLE
TABLET; ORAL
GANTANOL

	+	ROCHE	500MG	N12715 002	NOV 17, 1961	MAY	CTEC

SULFAMETHOXAZOLE

		@ GENEVA PHARMS	500MG	N85844 001	MAR 23, 1978	MAY	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM
SUSPENSION; ORAL
TRIMETH/SULFA

		@ NASKA	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

		@ TEVA	400MG;80MG	N18242 001	MAY 19, 1981	MAY	DISC
		@	800MG;160MG	N18242 002	MAY 19, 1981	MAY	DISC

SULFANILAMIDE
CREAM; VAGINAL
AVC
AT + NOVAVAX 15% N06530 003 JAN 27, 1987 JAN CAHN
SUPPOSITORY; VAGINAL
+ NOVAVAX 1.05GM N06530 004 JAN 27, 1987 JAN CAHN

SULFISOXAZOLE
TABLET; ORAL
SULFISOXAZOLE
@ GENEVA PHARMS 500MG N85628 001 JUN 13, 1977 JUL DISC

TECHNETIUM TC-99M APCITIDE
INJECTABLE; INJECTION
ACUTECT
BERLEX LABS N/A N20887 001 SEP 14, 1998 MAY CAHN
DIATIDE RES LABS N/A N20887 001 SEP 14, 1998 APR CAHN
N/A N20887 001 SEP 14, 1998 JUL CAHN

TEMAZEPAM
CAPSULE; ORAL
RESTORIL
TYCO HLTHCARE 7.5MG N18163 003 OCT 25, 1991 JUN CAHN
AB 15MG N18163 001 FEB 27, 1981 JUN CAHN
AB + 30MG N18163 002 FEB 27, 1981 JUN CAHN

TERAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
TERAZOSIN HCL
AB TORPHARM EQ 1MG BASE N75498 001 APR 12, 2001 APR NEWA
AB EQ 2MG BASE N75498 002 APR 12, 2001 APR NEWA
AB EQ 5MG BASE N75498 003 APR 12, 2001 APR NEWA
AB EQ 10MG BASE N75498 004 APR 12, 2001 APR NEWA
AB ZENITH GOLDLINE EQ 1MG BASE N75614 002 JAN 30, 2001 JAN NEWA
AB EQ 2MG BASE N75614 001 JAN 30, 2001 JAN NEWA
AB EQ 5MG BASE N75614 003 JAN 30, 2001 JAN NEWA
AB EQ 10MG BASE N75614 004 JAN 30, 2001 JAN NEWA

TERBUTALINE SULFATE
TABLET; ORAL
BRETHINE
AB NOVARTIS 2.5MG N17849 001 MAY 17, 1976 JUN CFTG
AB + 5MG N17849 002 MAY 17, 1976 JUN CFTG
TERBUTALINE SULFATE
AB IMPAX LABS 2.5MG N75877 001 JUN 26, 2001 JUN NEWA
AB 5MG N75877 002 JUN 26, 2001 JUN NEWA

TETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
PANMYCIN
@ PHARMACIA AND UPJOHN 250MG N60347 001 SEP 28, 1954 MAY DISC
ROBITET

TETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL

	ROBITET						
	@ WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC
	@	500MG	N61734 002	JUN 06, 1973	MAY	DISC
	TETRACYCLINE HCL					
	@ DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC
	@	500MG	N62343 002	OCT 02, 1981	MAY	DISC
	@ EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC
	@ WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC
	@	500MG	N60768 002	NOV 07, 1977	MAY	DISC
	@ WYETH AYERST	250MG	N61685 001	DEC 11, 1972	JUL	DISC
	@	500MG	N61685 002	DEC 11, 1972	JUL	DISC

THIORIDAZINE HYDROCHLORIDE
TABLET; ORAL

THIORIDAZINE HCL						
@ CHELSEA LABS	10MG	N88561 001	MAY 11, 1984	JUL	DISC
@ TEVA	10MG	N88493 001	MAY 17, 1985	JUL	DISC
@ ZENITH GOLDLINE	50MG	N88194 001	APR 14, 1983	JUL	DISC

THIOTEPA
INJECTABLE; INJECTION

THIOPLEX						
AP + IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG
THIOTEPA						
AP BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
AP GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA
+	30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA
@ IMMUNEX	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC

THYROGLOBULIN
TABLET; ORAL

THYROGLOBULIN						
@ IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC

TICARCILLIN DISODIUM
INJECTABLE; INJECTION

TICAR						
@ SMITHKLINE BEECHAM	EQ 3GM BASE/VIAL	N62690 001	DEC 19, 1986	MAY	DISC

TOBRAMYCIN
SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN						
@ ALCON UNIVERSAL	0.3%	N63176 001	MAY 25, 1994	MAY	DISC

TOBRAMYCIN SULFATE
INJECTABLE; INJECTION

>A>	NEBCIN						
>D>	+ LILLY	EQ 1.2GM BASE/VIAL	N50519 001	JUN 11, 1979	AUG	CFTG
>A>	AP +	EQ 1.2GM BASE/VIAL	N50519 001	JUN 11, 1979	AUG	CFTG
>A>	TOBRAMYCIN						
>A>	AP PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013 001	AUG 17, 2001	AUG	NEWA

TOBRAMYCIN SULFATE
INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

>D>	AP	ASTRAZENECA	EQ 10MG BASE/ML	N63119 001	OCT 31, 1994	AUG	DISC
>A>		@	EQ 10MG BASE/ML	N63119 001	OCT 31, 1994	AUG	DISC
		@	EQ 40MG BASE/ML	N63121 001	OCT 31, 1994	MAY	DISC
		@ ELKINS SINN	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	MAY	DISC
		@	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	MAY	DISC
		@ LEDERLE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	MAY	DISC

TOLMETIN SODIUM
CAPSULE; ORAL
TOLMETIN SODIUM

	@ GENEVA PHARMS	EQ 400MG BASE	N73462 001	APR 30, 1992	JUL	DISC

TOPIRAMATE
TABLET; ORAL
TOPAMAX

+	JOHNSON RW	25MG	N20505 004	DEC 24, 1996	MAR	CRLD
		200MG	N20505 002	DEC 24, 1996	MAR	CRLD

TRAVOPROST
SOLUTION/DROPS; OPHTHALMIC
TRAVATAN

+	ALCON UNIVERSAL	0.004%	N21257 001	MAR 16, 2001	MAR	NEWA

TRIAMCINOLONE
TABLET; ORAL
TRIAMCINOLONE

	@ IMPAX LABS	4MG	N84340 001	APR 22, 1975	FEB	DISC

TRIAMCINOLONE ACETONIDE
CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

	@ TARO	0.025%	N40038 001	OCT 26, 1994	MAY	DISC
	@ TOPIDERM	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP
	@	0.1%	N89275 001	FEB 21, 1989	FEB	WDRP
	@	0.5%	N89276 001	FEB 21, 1989	FEB	WDRP

OINTMENT; TOPICAL
ARISTOCORT

	@ FUJISAWA HLTHCARE	0.5%	N80745 002	MAY 28, 1974	JUL	DISC

ARISTOCORT A

	@ FUJISAWA HLTHCARE	0.5%	N80745 003	SEP 23, 1975	JUL	DISC

TRIAMCINOLONE ACETONIDE

	@ G AND W LABS	0.025%	N89795 001	DEC 23, 1988	JUL	DISC
	@	0.1%	N89796 001	DEC 23, 1988	JUL	DISC
AT	THAMES	0.025%	N40374 001	JUN 05, 2001	JUN	NEWA
AT		0.5%	N40386 001	JUN 05, 2001	JUN	NEWA

SPRAY; TOPICAL
KENALOG

+	APOTHECON	0.147MG/GM	N12104 001	DEC 24, 1959	JUL	CDFR

	TRICHLORMETHIAZIDE						
	TABLET; ORAL						
	TRICHLOREX						
	@ LANNETT	4MG	N83436 001	AUG 11, 1980	MAY	DISC	
	@	4MG	N85630 001	MAY 16, 1977	FEB	WDRP	
	TRIFLUOPERAZINE HYDROCHLORIDE						
	CONCENTRATE; ORAL						
	TRIFLUOPERAZINE HCL						
	@ GENEVA PHARMS	EQ 10MG BASE/ML	N85787 001	APR 15, 1982	MAY	DISC	
	TABLET; ORAL						
AB	GENEVA PHARMS TECH	EQ 1MG BASE	N40153 001	OCT 25, 1996	JAN	CAHN	
AB		EQ 2MG BASE	N40153 002	OCT 25, 1996	JAN	CAHN	
AB		EQ 5MG BASE	N40153 003	OCT 25, 1996	JAN	CAHN	
AB		EQ 10MG BASE	N40153 004	OCT 25, 1996	JAN	CAHN	
	TRIMETHOBENZAMIDE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	TRIMETHOBENZAMIDE HCL						
	@ STERIS	100MG/ML	N86577 001	OCT 19, 1982	JUL	DISC	
	TRIMETHOPRIM HYDROCHLORIDE						
	SOLUTION; ORAL						
	PRIMSOL						
	@ ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001	JUN 23, 1995	JUN	DISC	
	TRIMIPRAMINE MALEATE						
	CAPSULE; ORAL						
	SURMONTIL						
>A>	SIDMAK LABS	EQ 25MG BASE	N16792 001	JUN 12, 1979	AUG	CAHN	
>A>		EQ 50MG BASE	N16792 002	JUN 12, 1979	AUG	CAHN	
>A>	+	EQ 100MG BASE	N16792 003	SEP 15, 1982	AUG	CAHN	
>D>	WYETH AYERST	EQ 25MG BASE	N16792 001	JUN 12, 1979	AUG	CAHN	
>D>		EQ 50MG BASE	N16792 002	JUN 12, 1979	AUG	CAHN	
>D>	+	EQ 100MG BASE	N16792 003	SEP 15, 1982	AUG	CAHN	
	TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)						
	CREAM; VAGINAL						
	TRIPLE SULFA						
	@ FOUGERA	3.7%;2.86%;3.42%	N86424 001	MAY 31, 1979	JUN	DISC	
	TRIPTORELIN PAMOATE						
	INJECTABLE; INTRAMUSCULAR						
	TRELSTAR						
	+ DEBIO RECHERCHE	11.25MG/VIAL	N21288 001	JUN 29, 2001	JUN	NEWA	
	TRELSTAR DEPOT						
	+ DEBIO RECHERCHE	EQ 3.75MG BASE/VIAL	N20715 001	JUN 15, 2000	JUN	CDFR	
	URACIL MUSTARD						
	CAPSULE; ORAL						
	URACIL MUSTARD						
	@ SHIRE PHARM	1MG	N12892 001	SEP 13, 1962	JUN	DISC	

	UREA, C-13							
	FOR SOLUTION; ORAL							
>A>	BREATHTEK UBT FOR H-PYLORI							
>A>	+ MERETEK	EQ 75MG /POUCHE	N20586 002	MAY 10, 2001	AUG	NEWA		
>D>	MERETEK UBT KIT (W/ PRANACTIN)							
>D>	+ MERETEK	125MG/VIAL	N20586 001	SEP 17, 1996	AUG	DISC		
>A>	@	125MG/VIAL	N20586 001	SEP 17, 1996	AUG	DISC		
	VALGANCICLOVIR HYDROCHLORIDE							
	TABLET; ORAL							
	VALCYTE							
	+ SYNTEX (USA) INC LLC	EQ 450MG BASE	N21304 001	MAR 29, 2001	MAR	NEWA		
	VALPROIC ACID							
	CAPSULE; ORAL							
	VALPROIC ACID							
	@ PAR PHARM	250MG	N70431 001	FEB 28, 1986	MAY	DISC		
	@ SCHERER RP	250MG	N70195 001	JUL 02, 1987	JUL	DISC		
	VALSARTAN							
	TABLET; ORAL							
	DIOVAN							
	NOVARTIS	80MG	N21283 001	JUL 18, 2001	JUL	NEWA		
		160MG	N21283 002	JUL 18, 2001	JUL	NEWA		
	+	320MG	N21283 003	JUL 18, 2001	JUL	NEWA		
	VANCOMYCIN HYDROCHLORIDE							
	INJECTABLE; INJECTION							
	VANCOMYCIN HCL							
	@ ELKINS SINN	EQ 500MG BASE/VIAL	N62879 001	AUG 02, 1988	MAY	DISC		
	@	EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988	MAY	DISC		
	VINBLASTINE SULFATE							
	INJECTABLE; INJECTION							
	VELBAN							
	@ LILLY	10MG/VIAL	N12665 001	MAR 06, 1961	MAY	DISC		
	VINBLASTINE SULFATE							
AP	+ BEDFORD	10MG/VIAL	N89395 001	APR 09, 1987	MAY	CRLD		
	VITAMIN A PALMITATE							
	CAPSULE; ORAL							
	VITAMIN A							
	@ WEST WARD	EQ 50,000 UNITS BASE	N80967 001	MAY 04, 1973	FEB	WDRP		
	INJECTABLE; INJECTION							
	AQUASOL A							
>D>	+ ASTRAZENECA	EQ 50,000 UNITS BASE/ML	N06823 001	MAY 18, 1949	AUG	CAHN		
>A>	+ NEOSAN PHARMS	EQ 50,000 UNITS BASE/ML	N06823 001	MAY 18, 1949	AUG	CAHN		
	WARFARIN SODIUM							
	TABLET; ORAL							
	COUMADIN							
AB	DUPONT MERCK	2.5MG	N09218 018	NOV 29, 1961	JUL	CRLD		

>D>	AB +	5MG	N09218 007	FEB 17, 1964	AUG	CRLD
>A>	AB	5MG	N09218 007	FEB 17, 1964	AUG	CRLD
	AB +	5MG	N09218 007	FEB 17, 1964	JUL	CRLD

ZIPRASIDONE HYDROCHLORIDE
CAPSULE; ORAL
GEODON

	PFIZER	20MG	N20825 001	FEB 05, 2001	FEB	NEWA
		40MG	N20825 002	FEB 05, 2001	FEB	NEWA
		60MG	N20825 003	FEB 05, 2001	FEB	NEWA
	+	80MG	N20825 004	FEB 05, 2001	FEB	NEWA

ZOLEDRONIC ACID
INJECTABLE; IV (INFUSION)
ZOMETA

>A>	+ NOVARTIS	4.264MG/VIAL	N21223 001	AUG 20, 2001	AUG	NEWA

ZOLMITRIPTAN
TABLET, ORALLY DISINTEGRATING; ORAL
ZOMIG-ZMT

ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001	FEB	NEWA

ACETAMINOPHEN
SUPPOSITORY; RECTAL
ACETAMINOPHEN

	ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
		325MG	N18337 002	AUG 21, 1981	MAR	CAHN
+		650MG	N18337 001	APR 22, 1980	MAR	CAHN
	INFANTS' FEVERALL					
	ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
TAVIST ALLERGY/SINUS/HEADACHE

+	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA

ALCOHOL; CHLORHEXIDINE GLUCONATE
SOLUTION; TOPICAL
AVAGARD

+	3M	61%;1%	N21074 001	JUN 07, 2001	JUN	NEWA

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
BROMATAPP

@	COPLEY PHARM	12MG;75MG	N71099 001	JUL 02, 1987	JUL	DISC

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
TAVIST-D

@	NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
@		1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC

CLOTRIMAZOLE
CREAM; VAGINAL
TRIVAGIZOLE 3

	TARO	2%	N21143 001	APR 12, 2000	JUL	CRLD

CROMOLYN SODIUM
SPRAY, METERED; NASAL
CROMOLYN SODIUM

	ALPHARMA	5.2MG/INH	N74800 001	JUL 26, 2001	JUL	NEWA
	BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001	JUL 03, 2001	JUL	NEWA

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE

>A>	DR REDDYS LABS LTD	10MG	N75758 001	AUG 17, 2001	AUG	NEWA
	TEVA	10MG	N75312 001	MAY 31, 2001	MAY	NEWA
	ZENITH GOLDLINE	10MG	N75512 001	JUL 26, 2001	JUL	NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
IBUPROHM COLD AND SINUS

	OHM LABS	200MG;30MG	N74567 001	APR 17, 2001	APR	NEWA

INSULIN PURIFIED PORK
INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN
+ NOVO NORDISK 100 UNITS/ML N18381 001 MAR 17, 1980 MAY CTEC

INSULIN RECOMBINANT HUMAN
INJECTABLE; INJECTION
NOVOLIN R
+ NOVO NORDISK 100 UNITS/ML N19938 001 JUN 25, 1991 MAY CTEC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
INJECTABLE; INJECTION
HUMULIN 50/50
+ LILLY 50 UNITS/ML;50 UNITS/ML N20100 001 APR 29, 1992 MAY CTEC
NOVOLIN 70/30
+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19991 001 JUN 25, 1991 MAY CTEC

MICONAZOLE NITRATE
CREAM; TOPICAL
MONISTAT 3 COMBINATION PACK
+ PERSONAL PRODS 2%;4% N21261 001 FEB 02, 2001 FEB NEWA
CREAM; TOPICAL, VAGINAL
+ PERSONAL PRODS 2%;4% N21261 001 FEB 02, 2001 MAY CDFR
CREAM; VAGINAL

MINOXIDIL
SOLUTION; TOPICAL
MINOXIDIL EXTRA STRENGTH (FOR MEN)
PERRIGO 5% N75598 001 JUN 13, 2001 JUN NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST '01

NO AUGUST 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List

August 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
2-chloroethyl-3-sarcosinamide-1-nitrosourea TN=	Treatment for malignant gliomas	Lawrence Panasci, MD Professor of Medicine, McGill 3755 Cote Ste Catherine Montreal, Quebec H3T 1E2 DD= 8/3/01 MA=
2-methoxyestradiol TN=Panzem	Treatment of multiple myeloma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850 DD= 7/10/01 MA=
9-nitro-20-(S)-camptothecin TN=Camvirex	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc. P.O. Box 900 Germantown MD 20875-0900 DD= 5/15/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX TN=Coagulin-B	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX TN=Coagulin-B	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
adenovirus-mediated herpes simplex virus-thymidine kinase TN=	Use with gancyclovir in the treatment of malignant glioma	Ark Therapeutics Ltd 6 Warren Mews London W1T6AR UK DD= 7/31/01 MA=

Orphan Products Designations and Approvals List
August 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Alendronate disodium TN=Fosamax	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Children's Hospital Research Cincinnati OH 45229-3039 DD= 2/13/01 MA=
Angiotensin 1-7 TN=MARstem	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation 4041 MacArthur Boulevard, Suite Newport Beach CA 92660 DD= 8/3/01 MA=
augmerosen TN=Genasense	Treatment of multiple myeloma	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
augmerosen TN=Genasense	Treatment of chronic lymphocytic leukemia	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
augmerosen TN=Genasense	Treatment of acute myelocytic leukemia	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922 DD= 8/28/01 MA=
B Lymphocyte Stimulator TN=BLyS	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue Rockville MD 20850 DD= 2/21/01 MA=
beclomethasone 17,21-dipropionate TN=	Prevention of gastrointestinal graft-versus-host disease	Enteron Pharmaceuticals, Inc. 1680 Michigan Ave. Suite 700 Miami FL 33139 DD= 8/28/01 MA=

Orphan Products Designations and Approvals List
August 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide TN= Total Block VL SPF 75	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd. 677 W. Dekalb Pike King of Prussia PA 19406 DD= 8/13/01 MA=
Busulfan TN=Spartajet-Busulfan	Intrathecal therapy for neoplastic meningitis	SuperGen, Inc. 4140 Dublin Boulevard Dublin CA 94568 DD= 3/5/01 MA=
Coenzyme Q10 TN=	For the treatrment of Huntington's disease	Vitaline Corporation 385 Williamson Way Ashland OR 97520 DD= 3/5/01 MA=
docosahexanoic acid-paclitaxel TN=Taxoprexin	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377 DD= 3/5/01 MA=
Glatiramer acetate for injection TN=Copaxone	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA 1090 Horsham Road North Wales PA 19454 DD= 6/5/01 MA=
h5G1.1mAb TN=	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 DD= 3/5/01 MA=
Hsp E7 TN=	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655 DD= 3/19/01 MA=

Orphan Products Designations and Approvals List
August 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
human gammaglobulin TN=	Treatment for juvenile rheumatoid arthritis	Protein Therapeutics, Inc 9040 S. Rita Rd., Suite 1100 Tucson AZ 84747 DD= 5/25/01 MA=
Imatinib TN=Gleevec	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/31/01 MA= 5/10/01
Imexon TN= n/a	Treatment of metastatic malignant melanoma	AmpliMed Corporation 2321 Camino La Zorrela Tucson AZ 85718 DD= 8/3/01 MA=
INH-A00021 TN=	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Inhibitex, Inc. 8995 Westside Parkway Suite 150 Alpharetta GA 30004 DD= 6/13/01 MA=
Interferon-alfa-1b TN=	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery 9500 Euclid Avenue Clevland OH 44195 DD= 4/17/01 MA=
Intraoral fluoride releasing system TN=IFRS	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc. 1120 Win Drive Bethlehem PA 18017 DD= 7/31/01 MA=
L-glutamine TN=	Treatment of sickle cell disease	Orphan Drugs International, LLC PO Box 0401 Montrose CA 91021-0401 DD= 8/1/01 MA=

Orphan Products Designations and Approvals List
August 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Latrodectus immune F(ab)2 TN=Aracmyn	Treatment of black widow spider envenomations	Rare Disease Therapeutics, Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 6/18/01 MA=
Medroxyprogesterone acetate TN=Hematrol	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422 DD= 2/22/01 MA=
metreleptin TN=	Treatment of metabolic disorders secondary to lipodystrophy	Amgen, Inc., One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 8/22/01 MA=
metreleptin TN=	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 8/22/01 MA=
MTC-DOX for Injection TN=	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122 DD= 1/3/01 MA=
muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar liposomes TN=	Treatment of children and adolescent osteosarcoma	Jenner Biotherapies, Inc. 541 Kenosa Street Walworth WI 53184 DD= 6/5/01 MA=

Orphan Products Designations and Approvals List
August 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Nitroprusside TN=	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102 DD= 2/21/01 MA=
Novel Acting Thrombolytic (NAT) TN=	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 1/26/01 MA=
NZ-1002 TN=	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 4/11/01 MA=
p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt TN=	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd. Suite 470 Durham NC 27703 DD= 3/7/01 MA=
pemetrexed disodium TN=Alimta	Treatment of malignant pleural mesothelioma	Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 DD= 8/28/01 MA=
Perflubron TN=LiquiVent	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road San Diego CA 92191 DD= 4/26/01 MA=
Polyethylene glycol (PEG)-uricase TN=	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation 70 Wood Avenue South Iselin NJ 08830 DD= 2/21/01 MA=

Orphan Products Designations and Approvals List
August 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Pyruvate TN=	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 FIemington NJ 08822 DD= 2/21/01 MA=
recombinant human alpha-1 antitrypsin (rAAT) TN=	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	Baxter Healthcare Corporation 550 N. Brand Blvd. Glendale CA 91203 DD= 8/28/01 MA=
Recombinant Human Alpha-Fetoprotein TN=	Treatment of myasthenia gravis	Atlantic Biopharmaceuticals, Inc. 50 Church Street 5th floor Cambridge MA 02138 DD= 2/22/01 MA=
recombinant human endostatin protein TN=	Treatment of neuroendocrine tumors.	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850 DD= 8/13/01 MA=
Reviparin sodium TN=Clivarine	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=
Reviparin sodium TN=Clivarine	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=

Orphan Products Designations and Approvals List
August 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
squalamine lactate TN=	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation 5110 Campus Drive Plymouth Meeting PA 19462 DD= 5/11/01 MA=
Synthetic Human Parathyroid Hormone 1-34 TN=	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 1/26/01 MA=
Thyrotropin alfa TN=Thyrogen	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562 DD= 8/3/01 MA=
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 3/22/01 MA=
Vasoactive intestinal peptide TN=	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Health Sciences Center T17, 040 Stony Brook NY 11794-8172 DD= 3/9/01 MA=
Virulizin TN=Virulizin	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2 Canada DD= 2/1/01 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021205 001	ABACAVIR SULFATE;TRIZIVIR	6294540	MAY 14, 2018	U-65		
			6180639	JAN 30, 2018	U-248		
>ADD>	020977 001	ABACAVIR SULFATE;ZIAGEN	6294540	MAY 14, 2018	U-65		
>ADD>	020978 001	ABACAVIR SULFATE;ZIAGEN	6294978	MAY 14, 2018	U-65		
	021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
	021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
	020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012		I-235	SEP 23, 2001
						I-262	JUN 02, 2002
	021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
	020560 004	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
	021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010			
			6284770	OCT 05, 2018	U-405		
>ADD>	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
>ADD>			6291488	NOV 25, 2013			
			5053432	OCT 01, 2008			
>ADD>	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	6291488	NOV 25, 2013	U-406	NC	JUL 14, 2003
			5053432	OCT 01, 2008			
	019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		ODE	DEC 29, 2006
			5962731	OCT 05, 2016			
			5466861	NOV 14, 2012			
	020498 001	BICALUTAMIDE;CASODEX	1712251	SEP 18, 2001	U-391		
			5712251	SEP 18, 2001	U-391		
	021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
>ADD>	020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NCE	SEP 06, 2001
>ADD>						PED	MAR 06, 2002
>ADD>	020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415*PED	DEC 28, 2015	U-394	NCE	SEP 06, 2001
>ADD>			6248741*PED	DEC 28, 2015	U-394	PED	MAR 06, 2002
			6194415	JUN 28, 2015	U-394		
			6248741	JUN 28, 2015	U-394		
>ADD>	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415*PED	DEC 28, 2015	U-395	NP	MAR 16, 2004
>ADD>			5736165*PED	OCT 07, 2015	U-399	PED	SEP 16, 2004
>ADD>			5424078*PED	DEC 13, 2012		NCE	SEP 06, 2001
>ADD>			6248741*PED	DEC 28, 2015	U-395	PED	MAR 06, 2002
			5736165	APR 07, 2015	U-399		
			5424078	JUN 13, 2012			
			6248741	JUN 28, 2015	U-395		
			6194415	JUN 28, 2015	U-395		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020816 001	BRINZOLAMIDE;AZOPT	5378703	APR 01, 2012	U-224		
>ADD>	021324 001	BUDESONIDE;ENTOCORT				NP	OCT 02, 2004
	020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
	020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
	020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
	074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
	075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	076008 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	JAN 28, 2002
	020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX				I-333	JUN 06, 2004
	018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
			6265392	AUG 02, 2019			
			6274169	AUG 02, 2019			
	018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
			6265392	AUG 02, 2019			
			6274169	AUG 02, 2019			
	019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U-381		
	020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
>ADD>	020998 001	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
>ADD>	020998 002	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
	021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4847265	NOV 17, 2011			
020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U-402	NP	OCT 16, 2003
		5792753	AUG 11, 2015			
		5852002	JUN 17, 2014	U-402		
		5914322	AUG 11, 2015			
		5929048	JUL 27, 2016	U-402		
		5985850	NOV 16, 2016			
020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	NS	OCT 28, 2002
		5254539	AUG 29, 2006	U-248	PED	APR 28, 2003
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U-180		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020156 001	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	5985864	DEC 30, 2016			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	5985864	DEC 30, 2016			
021098 001	DROSPIRENONE;YASMIN	6248735	APR 17, 2011			
020706 001	EMEDASTINE DIFUMARATE;EMADINE				NC	MAY 11, 2004
020668 001	ENALAPRIL MALEATE;LEXXEL	4430343	AUG 14, 2005	U-403		
		5441958	DEC 08, 2013	U-404		
		4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
		4264611*PED	DEC 19, 2001	U-3		
		4803081*PED	OCT 03, 2007			
020668 002	ENALAPRIL MALEATE;LEXXEL	4374829	DEC 30, 2001	U-3		
		4472380	SEP 18, 2001			
		4703038	OCT 07, 2005	U-3		
		4803081	APR 03, 2007			
		4264611	JUN 19, 2001	U-3		
		4264611*PED	DEC 19, 2001	U-3		
		4803081*PED	OCT 03, 2007			
018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
	020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
>ADD>	019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
>ADD>	019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
>ADD>	019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
			4593119	JUN 03, 2003			
	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4508905	FEB 20, 2001			
	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4508905	FEB 20, 2001			
	020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
			6024976	JAN 07, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
			6024976	JAN 07, 2014			
	020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	5010070	APR 23, 2008		I-331	JUL 01, 2004
	020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	5010070	APR 23, 2008		I-331	JUL 01, 2004
>ADD>	021187 001	ETHINYL ESTRADIOL;NUVA RING				NP	OCT 03, 2004
	020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
	020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
						PED	FEB 11, 2004
	020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010			
	020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
			RE35524	MAY 17, 2010			
	020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
			RE35524	MAY 17, 2010			
	075312 001	FAMOTIDINE;FAMOTIDINE				PC	NOV 28, 2001
	020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
						PED	MAY 09, 2002
	019834 001	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4803081*PED	OCT 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
	019834 002	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019834 004	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
			4803081	APR 03, 2007			
			4264611*PED	DEC 19, 2001	U-3		
			4803081*PED	OCT 03, 2007			
>ADD>	021203 001	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009			
>ADD>	021203 003	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009			
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
>ADD>	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-340	OCT 10, 2004
	020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005			
>ADD>	074803 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 23, 2002
>ADD>	075049 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 23, 2002
>ADD>	075465 003	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 23, 2002
>ADD>	075506 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 23, 2002
>ADD>	075755 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 23, 2002
>ADD>	075755 002	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 23, 2002
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U-396	NDF	FEB 26, 2004
			5985322	MAY 29, 2017	U-397		
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
	021279 001	FORMOTEROL FUMARATE;FORADIL				NDF	SEP 25, 2004
						NCE	FEB 16, 2006
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
>ADD>	021061 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
>ADD>	021061 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
>ADD>	021062 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
>ADD>	021062 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
	021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
	021335 001	IMATINIB MESYLATE;GLEEVEC				NCE	MAY 10, 2006
						ODE	MAY 10, 2008
	021335 002	IMATINIB MESYLATE;GLEEVEC				NCE	MAY 10, 2006
						ODE	MAY 10, 2008
	021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014			
			5656722*PED	MAR 12, 2015			
	020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
	018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	020657 001	ITRACONAZOLE;SPORANOX				I-332	MAY 09, 2004
	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005		I-332	MAY 09, 2004
	019700 001	KETOROLAC TROMETHAMINE;ACULAR	4454151	MAR 22, 2002	U-75		
			5110493	MAY 05, 2009			
			4454151*PED	SEP 22, 2002	U-75		
			5110493*PED	NOV 05, 2009	U-75		
	020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE	4454151	MAR 22, 2002	U-75		
			4454151*PED	SEP 22, 2002			
	020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
	020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
>ADD>	021003 001	LAMIVUDINE;EPIVIR-HBV				PED	FEB 17, 2005
>ADD>						I-339	AUG 17, 2004
>ADD>	021004 001	LAMIVUDINE;EPIVIR-HBV				PED	FEB 17, 2005
>ADD>						I-339	AUG 17, 2004
	021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
	021281 002	LANSOPRAZOLE;PREVACID				D-42	JUL 20, 2001
						I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203		
	021088 001	LEUPROLIDE ACETATE;VIADUR	6235712	JUN 13, 2017			
	021226 001	LOPINAVIR;KALETRA	6232333	NOV 07, 2017			
			6284767	FEB 14, 2016	U-401		
	021251 001	LOPINAVIR;KALETRA	6284767	FEB 14, 2016	U-401		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
>ADD>	020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
>ADD>			5153197	OCT 06, 2009	U-3		
>ADD>			5608075	MAR 04, 2014			
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE				PC	JAN 12, 2002
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
>ADD>	021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD				NDF	APR 03, 2004
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			
	021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI	6153635	NOV 28, 2020			
			5514698	MAR 21, 2014			
	019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
			4313951*PED	MAY 26, 2002			
	021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
	020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-329	APR 27, 2004
	075179 001	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
	075189 001	NABUMETONE;NABUMETONE				PC	FEB 16, 2002
	075189 002	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
	019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
	019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
	021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
			5674710	OCT 07, 2014			
	020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
			5633008	JUN 14, 2008	U-389		
	020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
	019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
	019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
	019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
	019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
	019667 005	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
>ADD>	020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U-407		
	020592 001	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 002	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 003	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 004	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
			5605897	FEB 25, 2014	U-176		
			6251985	SEP 23, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020592 006	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149		
>ADD>			5605897	FEB 25, 2014	U-176		
			6251895	SEP 23, 2017			
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U-184		
	019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
	019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014			
			5629305*PED	AUG 04, 2014	U-166		
			6147103*PED	APR 09, 2019	U-188		
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019810 003	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		I-229	JUN 29, 2001
		6147103	OCT 09, 2018		PED	DEC 29, 2001
		6166213	NOV 10, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001	U-108		
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014	U-166		
		5629305*PED	AUG 04, 2014	U-188		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	4508905	APR 02, 2002			
		5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
		5866601	FEB 02, 2016		NDF	DEC 14, 2003
		5952375	FEB 02, 2016		NCE	OCT 27, 2004
020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
		6262115	MAY 22, 2015	U-393		
020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	NOV 13, 2007			
		5266331	FEB 05, 2008			
		5549912	FEB 05, 2008			
		5508042	APR 16, 2013			
020262 001	PACLITAXEL;TAXOL	5656295	FEB 05, 2008			
		6096331	FEB 22, 2013			
020036 001	PAMIDRONATE DISODIUM;AREDIA	6150398	MAY 08, 2011	U-380		
020036 003	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
020036 004	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
020987 001	PANTOPRAZOLE SODIUM;PROTONIX				D-68	AUG 20, 2004
020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV				I-330	JUN 12, 2004
		4758579	JUL 19, 2005		NDF	MAR 22, 2004
					NCE	FEB 02, 2005
					I-337	OCT 19, 2004

>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
		4839177	JUN 13, 2006			
		5422123	JUN 06, 2012			
		5789449	JAN 06, 2009	U-286		
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
		5547656	APR 05, 2011			
		5769080	JUL 20, 2010			
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
019627 002	PROPOFOL;DIPRIVAN				I-322	FEB 20, 2004
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385		
		5035899	APR 04, 2009	U-385		
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
019901 001	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
020741 001	REPAGLINIDE;PRANDIN	6143769	MAR 24, 2009			
020741 002	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
020741 003	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
020903 001	RIBAVIRIN;REBETOL	5767097	JAN 23, 2016	U-235	PED	JUN 09, 2002
		5914128	DEC 22, 2017		PED	DEC 03, 2001
		6051252	DEC 22, 2017			
		6063772	JAN 23, 2016	U-375		
		6172046	SEP 21, 2017	U-377		
		5767097*PED	JUL 23, 2016	U-235		
		5914128*PED	JUN 22, 2018			
		6051252*PED	JUN 22, 2018			
		6063772*PED	JUL 23, 2016	U-375		
		6172046*PED	MAR 21, 2018	U-377		
018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U-400		
020945 001	RITONAVIR;NORVIR	6232333	NOV 07, 2017			
021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
		5691374	NOV 25, 2017			
		6239173	JUN 24, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
			6239173	JUN 24, 2013			
			5474995	JUN 24, 2013	U-266		
	021052 001	ROFECOXIB;VIOXX	5691374	NOV 25, 2017			
	021052 002	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	020692 001	SALMETEROL XINAFOATE;SEREVENT	6239173	JUN 24, 2013			
	020828 001	SAQUINAVIR;FORTOVASE	5290815	MAR 01, 2011	U-386		
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5196438	NOV 19, 2010			
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
>ADD>	020478 001	SEVOFLURANE;ULTANE				M-11	AUG 06, 2004
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	6288127	JAN 27, 2017			
						D-65	FEB 16, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				M-9	FEB 16, 2004
						D-65	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				M-9	FEB 16, 2004
						D-65	FEB 16, 2004
>ADD>	021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL				M-9	FEB 16, 2004
>ADD>	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	5616346	MAY 18, 2013	U-359		
						I-334	JUL 25, 2004
>ADD>	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN				ODE	JUL 25, 2008
						I-334	JUL 25, 2004
>ADD>	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
			6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
			6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
			6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
						I-334	JUL 25, 2004
>ADD>	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
			6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
			6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
			6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
						I-334	JUL 25, 2004
>ADD>	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				ODE	JUL 25, 2008
						I-334	JUL 25, 2004
>ADD>						ODE	JUL 25, 2008

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008			
	020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	019964 001	TERCONAZOLE;TERAZOL 3	4358449	NOV 09, 2001			
	020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010			
			5602006	FEB 11, 2014			
			5658760	AUG 19, 2014			
			5240832	AUG 31, 2010			
			6114144	NOV 24, 2015			
			5840566	NOV 24, 2015			
	020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
	020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
	020505 001	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 002	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 003	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 004	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 005	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020505 006	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
						I-335	AUG 28, 2004
	020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020528 003	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020591 001	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 002	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 003	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 004	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
			5631287	DEC 22, 2014	U-382		
			5849792	DEC 22, 2014	U-383		
			5889052	AUG 03, 2013	U-383		
			6235781	JUN 15, 2019	U-382		
	019963 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
	021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
			4603146	JUL 29, 2003	U-131		
	020475 001	TRETINOIN;RETIN-A MICRO	5955109	SEP 21, 2016	U-134		
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6143329	JUL 03, 2016			
	021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP	JUN 29, 2004
			5192741	MAR 09, 2010		NCE	JUN 15, 2005
	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5776885	JUL 07, 2015			
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
>ADD>	020586 002	UREA, C-13;BREATHTEK UBT FOR H-	4830010	OCT 27, 2009	U-147		
>ADD>			5140993	AUG 24, 2009			
					U-148		
>ADD>	019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
>ADD>			4845077	JUL 04, 2006	U-408		
>ADD>			4725579	FEB 21, 2005	U-408		
>ADD>	019415 005	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
>ADD>			4845077	JUL 04, 2006	U-408		
>ADD>			4725579	FEB 21, 2005	U-408		
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
	021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
	021283 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398	I-325	MAY 02, 2004
	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013		I-325	MAY 02, 2004
	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398	I-325	MAY 02, 2004
	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398	I-325	MAY 02, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398	I-325	MAY 02, 2004
020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398	I-325	MAY 02, 2004
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017			
		5916923	JUN 28, 2013	U-398		
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
021119 001	VERTEPORFIN;VISUDYNE				I-336	AUG 22, 2004
020547 001	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
020547 003	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
020859 001	ZALEPLON;SONATA				M-8	FEB 22, 2004
020859 002	ZALEPLON;SONATA				M-8	FEB 22, 2004
020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
021223 001	ZOLEDRONIC ACID;ZOMETA				NCE	AUG 20, 2006
					ODE	AUG 20, 2008
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS

NEW INDICATION

I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5

MISCELLANEOUS EXCLUSIVITY CODES

M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER

PATENT USE CODES

U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODES

U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	METHOD OF USE OF LOTRONEX
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION

*U.S. Government Printing Office: 2001 — 491-214/40003

New 22nd Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8392

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS,** ADP, and the monthly Cumulative Supplements, for $105.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐-☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence